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SMALL MOLECULES AS NEGATIVE ALLOSTERIC MODULATORS OF 7 nAChRs 
 
By Osama Ibrahim Alwassil, M.S. 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
 
Major Director: Małgorzata Dukat, Associate Professor, Department of Medicinal Chemistry 
 
7 Neuronal nicotinic acetylcholine receptors (nAChRs) are involved in essential 
physiological functions and play a role in disorders such as Alzheimer’s disease. MD-354 (3-
chlorophenylguanidine; 21), the first small–molecule negative allosteric modulator (NAM) at 7 
nAChRs, served as a lead in developing structure–activity relationships for NAMs at 7 
nAChRs. MD-354 (21) also binds at 5-HT3 receptors. Analogs of MD-354 with structural 
features detrimental to 5-HT3 receptor affinity were evaluated in patch-clamp recordings and an 
aniline N-methyl analog resulted in a more potent and selective NAM than MD-354. A new N-
methyl series of compounds was synthesized in which the 3-position was replaced with different 
substituents considering their electronic, lipophilic, and steric nature. Comparative studies were 
initiated to investigate whether or not the MD-354 series and the N-methyl series bind in the 
 same manner; 3D models of the extracellular domain of human 7 nAChRs were developed, 
allosteric sites identified, and docking studies conducted. 
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I. Introduction 
 
 
 
Acetylcholine (ACh) is a widely distributed neurotransmitter in the nervous system. Prior 
to its recognition as a neurotransmitter, ACh was chemically synthesized in 1867 and was later 
isolated as a naturally occurring choline ester.1,2 The theory of chemical neurotransmission in 
1936 was the point at which ACh first became known as a neurotransmitter.2,3 Acetylcholine 
receptors (AChRs) were later identified and classified as nicotinic acetylcholine receptors 
(nAChRs) and muscarinic acetylcholine receptors (mAChRs). nAChRs belong to the ligand-
gated ion-channel (LGIC) receptor superfamily, whereas mAChRs are members of the G-protein 
coupled receptor (GPCR) superfamily.2 7 nAChRs are one of the major subtypes of neuronal 
nAChRs, and are found predominantly in the central nervous system and are a recognized target 
for cognitive enhancement.4 
 
The LGIC superfamily of receptors is characterized by a very rapid cellular response 
upon exposure to agonists. Within this process of activation, the receptor undergoes a 
conformational change that provides the optimum condition for a specific ion to pass through the 
receptor’s pore. The passage of a particular number of ions causes the surrounding membrane to 
become depolarized. Neuronal 7 nAChRs are usually localized in nerve ending regions as are 
 
 
2 
 
other neurotransmitter receptors such as dopamine, glutamate, and γ-aminobutyric acid (GABA) 
receptors.4 The nerve ending regions can stimulate the release of ACh as well as co-existing 
neurotransmitters as a consequence of the change in their polarity under the activation of 7 
nAChRs. The release of more than one neurotransmitter upon 7 nAChR stimulation indicates 
one side of the functional complexity of these receptors.4 
 
7 nAChRs have some unique features that distinguish the receptor subtype from other 
nAChR subtypes. 7 nAChRs are characterized by a high Ca2+/Na+ permeability ratio and rapid 
desensitization.5 In contrast to the 42 nAChR subtype that has a low affinity for the 
competitive antagonist -bungarotoxin (-BTx) and a high affinity for the agonist (-)-nicotine, 
7 nAChRs have a high affinity for -BTx, and low affinity for (-)-nicotine. Furthermore, 7 
nAChRs can be fully activated by choline whereas choline does not activate 42 nAChRs.6 
 
The distribution of 7 nAChRs in the central nervous system (CNS) as well as in the 
peripheral nervous system (PNS) suggests their involvement in the etiology of several diseases 
such as Alzheimer’s disease (AD), schizophrenia, Parkinson’s disease, depression, nicotine 
dependence, pain, inflammation, and lung cancer.6 Many 7 nAChR agonists and antagonists are 
recognized as possible candidates for the treatment of cognitive dysfunction.7,8 Positive allosteric 
modulators (PAM) of 7 nAChRs, a class of compounds that enhance the activity of the 
endogenous agonist acetylcholine (ACh) without direct activation of the receptors, have been 
proposed as a potential treatment for cognitive diseases in both the clinical and the preclinical 
phase.7 Yet, another unexplored approach might involve negative allosteric modulators (NAMs). 
However, until very recently, such agents were not known. 
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 m-Chlorophenylguanidine (mCPG; MD-354) was identified in our laboratory as the first 
small–molecule negative allosteric modulator of 7 nAChRs (IC50 = 7.98 µM).9 In addition to its 
inhibitory activity at 7 nAChRs, MD-354 possesses high affinity at 5-HT3 receptors (Ki = 35 
nM). Because of the selectivity problem, it was crucial to investigate if removal/addition of an 
MD-354 structural component required for 5-HT3 receptor binding could result in a compound 
that retains inhibitory activity at 7 nAChRs and, at the same time, reduce 5-HT3 receptor 
affinity. 
 
 As an important tool in medicinal chemistry, molecular modeling studies were initiated to 
examine interaction site(s) and mechanisms by which the 7 nAChR NAMs work. Three-
dimensional (3D) models of the extracellular domain (ECD) of human 7 nAChRs were 
constructed based on the ECD of a mouse 1 nAChR subunit crystal structure. The results of 
cavity-search studies and docking solutions should allow for further insight at 7 nAChR 
allosteric sites and provide an impact on a way to develop novel small–molecule NAMs.  
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II. Background 
 
 
 
A. Acetylcholine  History 
 
Acetylcholine (ACh; 1) (Figure 1) is an endogenous substance classified as an ester of an 
acid and quaternary ammonium alcohol, acetic acid and choline, respectively.  It was initially 
prepared by a German chemist, Adolf von Baeyer, who chemically synthesized it in 1867.1,2 The 
natural occurrence of this compound was not recognized until 1914 from plant material 
contaminated by ergot fungus.10 The compound became known for its action in mediating 
parasympathetic transmission in the frog heart and, then, was the first neurotransmitter to be 
identified when the concept of chemical neurotransmission gained popularity between 1921 to 
1925.2,3 
 
 
 
1 
 
 
Figure 1. The structure of acetylcholine (ACh; 1). 
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Many attempts were made, in the years thereafter, to obtain evidence for the existence of 
acetylcholine in the central nervous system (CNS) of animals. In the mid 1960’s, a new 
technology, gas chromatography–mass spectrometry (GC-MS), was first introduced and using 
this technology on rat tissue, Holmstedt and co-workers were successful in reporting the first 
isolation of acetylcholine from fresh mammalian brain.11 
The action of acetylcholine in the body varies depending mainly on the release location 
and the acetylcholine receptor type.12 This change in acetylcholine behavior resulted in 
narrowing its therapeutic indication to limited ophthalmic practices.13 
 
 
B. Cholinergic Receptors 
The acetylcholine receptors are divided into two major classes, nicotinic acetylcholine 
receptors (nAChRs) and muscarinic acetylcholine receptors (mAChRs), based on their selective 
response to two alkaloids: nicotine (2) and muscarine (3) (Figure 2). The two classes of 
cholinergic receptors are structurally, as well as functionally, different with other unique 
properties characterizing each of them. Intensive studies throughout the years have been made on 
both of the two classes aiming to achieve a better understanding of their role in neuronal 
terminals and possible therapeutic advantages that could be gained.12 Cholinergic receptors  are 
 
 
 
 
 
Figure 2. The structures of nicotine (2) and muscarine (3). 
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3 
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widely distributed in the CNS and are considered as important targets in the treatment of a 
number of diseases including schizophrenia and Alzheimer's disease (AD).7,14 
 
 
1. Muscarinic Acetylcholine Receptors (mAChRs) 
 
The mAChRs are homologs of rhodopsin, the visual pigment, and are members of the 
superfamily of G-protein coupled receptors (GPCRs) that are structurally described as a 
heptahelical integral membrane protein subunit that is essential in conducting signals across cell 
membranes.12 The wide distribution of these receptors, especially in the CNS, attracts attention 
to the significance of mAChRs that is supported by their impact in regulating dopaminergic 
systems.14 There are five identified subtypes of these receptors assigned as M1–M5 based on the 
order of their discovery.15 Functionally, the subtypes M1, M3, and M5 couple preferentially to 
Gq proteins for the activation of second messenger phospholipase C (PLC) and the release of 
inositol (1,4,5)-triphosphate (IP3) that increases the level of intracellular calcium.15  On the other 
hand, the subtypes M2 and M4 primarily couple to Gi/o proteins that leads to a negative 
downstream signaling on adenylate cyclase which decreases the formation of the second 
messenger 3',5'-cyclic adenosine monophosphate (cAMP) and, eventually, decreases the level of 
intracellular calcium.14,15 
 
2. Nicotinic Acetylcholine Receptors (nAChRs) 
The nAChRs are members of the ligand-gated ion channel (LGIC) superfamily of 
receptors that mediate fast synaptic transmissions of neurotransmitters. Although the amount of 
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expression of the mAChRs subunits in the CNS is significantly higher than that of the nAChRs, 
nAChRs play a vital role in many physiological and pathophysiological processes.16 
 
 
a. History and Classification 
 
nAChRs are the classical and the most studied members of the LGIC superfamily of 
receptors. The large number of studies are probably related to the accessibility of the receptor, 
particularly from the electric organ of the Electrophorus fish and the Torpedo marine ray.17 The 
first nAChR to be isolated and characterized was in 1970 by Changeux et al.18 using a detergent 
extraction technique. Purification and reconstitution techniques were developed later, 1972-1980, 
with a more detailed characterization of the primary structure of nAChR subunit composition.18 
In 1981, Sumikawa et al.19 were successful in expressing Torpedo electric organ messenger 
ribonucleic acid (mRNA) in Xenopus oocytes. The latter achievement boosted efforts toward the 
molecular cloning of functional nAChRs and, later, between 1982–1983, this resulted in the 
separation of a number of complementary deoxyribonucleic acids (cDNAs) encoding the four 
subunits of the Torpedo electric organ nAChR (i.e., , , γ and  subunits).17 Subsequently, 
many investigators were able to clone nAChR subunit cDNAs of numerous other species.17 The 
human 7 nAChR subtype, for example, was first stably expressed for functional and 
pharmacological evaluation in human embryonic kidney 293 (HEK-293) cell lines by 
Gopalakrishnan et al. in 1995.20 
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Among the seventeen nAChR subunits of vertebrate species that have been identified, 
1-10, 1-4, γ,  and ε, a diverse family of nAChR subtypes can be generated by several 
different subunit combinations. With the exception of 8, which exists only in avian species, all 
of these identified subunits are present in humans as well as in other mammalian species. The 
assignment of the Greek letters (i.e., , , γ,  and ε) basically arises from the first 
characterization of nAChR subunits in the electric organ of the Electrophorus fish and the 
Torpedo marine ray and were assigned based on the order of the molecular weight of each 
subunit.21  
 
 
b. Nomenclature 
 
Although the Greek-letter assignments were primarily based on the order of the 
molecular weight of each subunit at the specific conditions at which the subunits were initially 
purified, several criteria were later used to recognize these subunit types. The criteria for the  
subunit includes the presence of two adjacent cysteine residues (Cys192 and Cys193), and the 
ability to be labeled by quaternary ammonium affinity-labeling reagents (i.e., an agonist binding 
subunit).21 The 2-4 subunits are described as the non- subunit that is expressed exclusively in 
the vertebrate nervous system, whereas 1, γ,  and ε subunits are defined as any non- subunit 
expressed at the neuromuscular junction of vertebrates (Figure 3).16 However, some limitations 
have been reported in this process of nomenclature such as the lack of agonist binding ability at 
5 and 10 subunits, and the inability to describe the exact stoichiometry of some receptor-like 
42 proteins.21 
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Figure 3. The classification of the two receptor classes of AChRs.16 
 
The high number of identified nAChR subunits increases the probability of many 
different combinations of subunits to form pentamers with in vivo expression.21,22 However, the 
ability of many subunits to form different pentamers is not enough to be considered as receptors. 
The subunit combinations should accompany the functional ability of the formed pentamer. 
Moreover, the differences of the subunits’ combination order affect the pharmacological 
properties of the receptor (e.g., agonist and antagonist sensitivity).21 This added another 
challenge to the nomenclature to find a method to describe the different composition and 
stoichiometry of nAChRs.16,23 Lukas et al.,24 in a working International Union of the 
Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR), 
recommended the use of an asterisk as a “wild card” at the end of receptor name (e.g., 42*) to 
indicate possible additional subunits that might be present in a neuronal nAChR complex. The 
exact composition and stoichiometry, if known, could also be described using a subscript number 
(e.g., (1)21γ  receptor).21,24 
 
ACh Receptors 
Muscarinic 
(GPCRs) 
Nicotinic 
(LGICRs) 
M1 M2 M3 M4 M5 Neuronal Non-neuronal 
2-10 2-4 1 1 γ δ ε 
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The 7, 42, and 34 receptors are the most common neuronal nAChR subtypes.21 
The 7 receptor subtype is a pentamer that is considered as the most abundant homomeric 
nAChR in the central nervous system.21  42 Receptors are heteromeric receptors that are the 
major nAChRs in mammalian brain.21 On the other hand, a common heteromeric nAChR (i.e., 
34) represents the most abundant nAChRs in the autonomic ganglia, adrenal medulla, and in 
regions of the dorsal medulla, pineal gland, medial habenula, nucleus interpeduncularis, and 
retina.21  
 
Despite that most of the nAChRs exist presynaptically, to enhance neurotransmitter 
release, postsynaptic nAChRs play an important role in fast excitatory transmission.16,25 The 
activation of these receptors causes membrane depolarization through direct calcium influx or an 
indirect process which is mediated by voltage-dependent calcium channel (VDCC) activation.25 
Downstream induction of calcium from the endoplasmic reticulum (ER) in a process called 
calcium-induced calcium release (CICR), mediated by ryanodine receptors and inositol (1,4,5)-
triphosphate receptor (IP3R) second-messenger systems, might also be involved.25  The previous 
three routes control the cytoplasmic calcium level that contributes in many downstream cascade 
events on calcium-dependent kinases (e.g., protein kinase C (PKC), and extracellular-signal 
regulated kinase/mitogen-activated protein kinase (ERK/MAPK), and the transcription factor 
CREB (cAMP response element-binding protein). These signaling molecules, eventually, 
participate in many significant processes that include neurotransmitter release, recovery of 
nAChR desensitization, and gene expression.16,25  
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c. Ligand-Gated Ion-Channel (LGIC) Receptors 
 
The LGIC group of receptors is a superfamily of receptors that includes Cys-loop 
receptors, ionotropic glutamate receptors (GluR), and ATP-gated purine receptors (P2X).26 The 
extensive characterization of nAChRs was the major basis to rank the LGIC group as the best 
known of receptor families.26,27 nAChRs are considered as cationic-selective channels that 
belong to the Cys-loop receptor group which also includes serotonin 5-HT3 receptors, and both 
of these receptor are responsible for conducting excitatory signals. On the other hand, the anionic 
selective channels of the Cys-loop receptor group include GABAA, GABAC and glycine 
receptors and these receptors are responsible for conducting inhibitory synaptic activity. Both 
cationic and anionic receptors belong to the Cys-loop group due to their shared feature of a 15-
residue-spacing of two cysteine amino acids that are connected by a disulfide bridge.27 All of the 
above classifications of LGIC receptors are based on ion selectivity, amino acid sequence 
homology, and agonist selectivity.28 
 
 Recent crystallization techniques, and other structural determination methods of ACh-
binding protein (AChBP), have had a great impact in defining the molecular detail of nAChRs. 
Structurally, the nAChR is constructed of five subunits (i.e., a pentameric receptor), assembled 
symmetrically around a central channel.22 Each nAChR consists of three major domains: an 
extracellular domain (ECD), a transmembrane domain (TM), and an intracellular domain (ICD) 
(Figure 4). The ECD of the nAChR subunit is about 200 residues long and, based on the 
similarity and differences of the subunits, the receptor could be a homomeric receptor (e.g., 7 
nAChR), or a heteromeric receptor (e.g., 42 nAChR), respectively.29,30 The TM protein of 
 
 
12 
 
each subunit is formed of four transmembrane-spanning helices (M1-M4), whereas the ICD is 
made up primarily from the intracellular loops of TMs, mainly from the short intracellular loop 
connecting M1 to M2 and, to a larger extent, the long intracellular loop connecting M3 to M4 
(Figure 5).29,31 From each of the five subunits that form the receptor, there are hydrophilic amino 
acids lining the M2 ends that shape an intracellular and/or an extracellular ring that determines, 
to some extent, the ion selectivity of the receptor channel.5 The ECD has attracted the most 
attention since it contains the putative binding site (i.e., the orthosteric site) for  many ligands, 
including ACh.5 Numerous studies demonstrated that the orthosteric binding site is mainly 
formed by the interface between the -subunit with the contribution of residues from loops A, B, 
and C (i.e., the principal or (+) site of the binding pocket), and the neighboring subunit residues 
with the contribution of loops D, E, and F (i.e., the complementary or (-) site of the binding 
pocket) (Figure 4).32  
 
 The exact three-dimensional description of nAChRs is a useful tool for the design of 
novel drugs that aim to treat diseases such as AD. Several studies on Torpedo nAChR electron 
microscopy data and the crystal structure of the AChBP were able to determine nAChR 
dimensions.30,33,34 Each nAChR subunit is about 62 Å high, 47 Å wide, and 34 Å thick.30 The 
diameter of the pentamer is 80 Å, whereas the diameter of the central pore is around 18 Å.30,33 
Fluorescence resonance energy transfer (FRET) was used to determine the position of the 
orthosteric cavity which is located above the membrane surface by about 30 Å.35 
 
 Upon functioning, nAChRs undergo certain structural changes that reflect the level of 
activation that the receptor adopts. The allosteric nature and the dynamics of nAChRs were 
explained by the Monod-Wyman-Changeux (MWC) model.36,37 According to the MWC  
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Figure 4. Structural description of nAChRs based on molecular modeling. (A) A whole receptor 
representation adopted from PDB (PDB ID: 2BG9B) including the three main domains; the 
ECD, the TM domain, and the ICD. (B) A top view of five different colored subunits forming the 
receptor. (C) The orthosteric binding site formed by loops located at the interface between the 
two subunits; the principal subunit ribbon colors: Red, loop A; blue, loop B; yellow, loop C; the 
complementary subunit ribbon colors: green, loop D; orange, loop E; purple, loop F. 
 
 
model, there are three main states in which nAChRs exist: the resting state (R), the active state 
(A), and the desensitized state (fast-onset (I) and slow-onset (D)) (Figure 6).16 The transition of 
nAChRs between one state and another is regulated by the free energy differences which are 
(A) (B) 
(C) 
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affected by the existence of interacting ligand in the receptor’s vicinity.16 nAChR agonists and 
antagonists stabilize the active and the resting state, respectively. However, the active state of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Structural details of the nAChR. (A) A side view representation of the pentameric 
arrangement of the subunits around the pore. (B) Schematic depiction of the secondary structures 
of the nAChR subunit including the exact order of  helices,  sheets, and loops connecting 
them in three main domains (i.e., ECD, TM, ICD). (C) Top view representation of the TM 
domains of the pentameric receptor showing M2 of each subunit lining the receptor pore.16,26  
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nAChRs can occur without the existence of interacting agonists (i.e., constitutive activity).16 The 
conformational changes in nAChRs caused by different ligands have been the target of many 
comparative analyses and molecular dynamics studies.38,39 The closure and the extension of loop 
C upon activation and inhibition of the receptor, respectively,  was clearly detected as the most 
marked conformational change after the interaction of ligand with the binding pocket.  
 
Most of the structural data were originally obtained or confirmed by crystal structures 
that were published in recent years.31 The crystallographic techniques were originally based on 
data coming from low- to medium-resolution electron microscopy studies on Torpedo receptors 
and provided only general information on the structure and size of the receptor, the ligand 
interaction site, and the arrangement of the secondary structure around the receptor pore. In 
2001, Brejc et al.30 were able to provide the crystal structure of molluscan AChBP.  Also, Unwin 
had a great impact on this field when he published the first molecular model of the Torpedo 
AChR at 4 Å resolution using cryo-electron microscopy in 2005.40 A recent, important crystal 
structure determination was reported by Dellisanti et al.32 on the ECD of the mouse 1 nAChR 
in the closed state at 1.94 Å resolution. The crystallized protein is a good template for the 
molecular modeling of the ECD of human 7 nAChR since it shares a 38% sequence identity.32 
 
The expression and distribution of nAChR subunits show a high level of 7 receptors in 
the brain, the second most common nAChR in brain after 42 nAChRs, which accounts for 
90% of neuronal nAChRs. The cortex, hippocampus, and subcortical limbic area is the primary 
localization of the 7 subunit, while low levels of the subunit are reported in the thalamic area 
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and basal ganglia.16,41,42 The assembly and expression of  another participant subunit in the 
formation of 7 nAChRs might affect either the ion selectivity and desensitization properties of   
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Representation of the different states of the MWC model that explain the allosteric 
nature of nAChRs; the resting state (R), the active state (A), the fast-onset desensitized state (I), 
and the slow-onset desensitized state (D).16 
 
the newly formed heteromeric receptor.5 Although the human 7 nAChR subtype was first 
expressed in 1995, 42 and  ()2γ subunits were first successfully expressed in mouse 
fibroblasts (i.e., M8 and AM4 cell lines) three years before.20,43,44  The  existence  of  these 
different  expressed  subunits  in  distinct  areas  in  the CNS and/or in the periphery with 
dissimilar conditions can vary significantly the precise function that these receptors play in 
normal physiological states as well as in the development of many diseases.5 
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The distribution of 7 nAChRs in brain regions involved in cognitive function and 
emotional behavior indicates a strong relationship between some CNS diseases and the 
pathophysiological state of these receptors.20 Alzheimer disease (AD) is one of the diseases 
assumed to be a consequence of abnormalities in 7 nAChR signaling which appears in patients 
as general cognitive impairments accompanied by an episodic decline in memory.45 Several 
studies suggest that the progression of AD is associated with an increase of -amyloid peptide 1-
42 (A1-42) interactions with 7 nAChRs leading to downstream signaling that causes tau protein 
hyperphosphorylation, the structural protein stabilizing the microtubules, and neuronal 
degeneration.46 This harmful interaction and signaling have been the target of many studies that 
tested a number of novel 7 nAChR ligand effects. 7 nAChR agonists and positive allosteric 
modulators (PAMs) were proposed as possible therapeutic agents for AD patients through their 
ability to prevent toxic 7 nAChR–A1-42 interactions and their activation to the neuroprotective 
pathway in 7 nAChR downstream signaling. Despite that most of the reported results were 
focused on the successful desired effect of 7 receptor agonists and PAMs targeting AD therapy, 
low doses of 7 receptor antagonists have been reported to produce a similar desired effect.45-47 
Methyllycaconitine (MLA), an example of an 7 nAChR antagonist, shows a neuroprotective 
role which suggests that the neuroprotective pathways were originally due to a 
desensitization/inactivation mechanism on 7 nAChRs.48 The hippocampus and cortex are the 
key brain regions at which the AD experiments are taking place since they represent the major 
memory processing regions and the primary expression sites for 7 nAChRs.47  
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d. 7 nACh Receptor Agonists 
 
A number of naturally-occurring alkaloids represent the earlier, nonselective, and high 
affinity agonists for nAChRs:  (-)-nicotine (2) (Figure 2), (-)-lobeline (LOB; 4) and (±)-
epibatidine (EPI; 5) (Figure 7) are some examples of these alkaloids that have been extensively 
studied to understand their molecular role in activating nAChRs.16,49,50 From such studies, 
agonist selectivity for 42 and 7 nAChRs was found to be highly dependent on local binding 
and long-range electrostatic interactions between the receptors and the protonated portion or the 
cationic part of the agonist structures.51 Detailed information of the atomic interactions guided 
the synthesis of novel, highly selective agonists targeting nAChR subtypes. 50  
 
Figure 7. The chemical structures of selective and nonselective 7 nAChR agonists: (-)-lobeline 
(LOB; 4), (±)-epibatidine (EPI; 5), TC-1698 (6), tropisetron (7), AR-R17779 (8), PNU-282987 
(9), and GTS-21 (10). 
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The primary work of many medicinal chemistry practices in the field of nAChRs took 
place on a series of novel compounds based on the nicotine (2) and epibatidine (5) skeletons. The 
replacement of the pyrrolidine group of nicotine with an azabicyclo[3.2.2]nonane ring (i.e., TC-
1698; 6) (Figure 7), for example, yielded a full agonist at 7 nAChRs (EC50 = 0.44 µM).16 
Among several challenges that faced the syntheses of novel 7 nAChR ligands, selectivity 
remains the biggest issue due to cross-activity with 5-HT3 receptors arising from the high 
homology in the orthosteric site between the two receptor types.16 The 5-HT3 receptor antagonist 
tropisetron (7) (Figure 7), for example, is a partial agonist at 7 nAChRs (EC50 = 0.38 µM).16 A 
derivative of quinuclidine structures, spirooxazolidinone AR-R17779 (8) (Figure 7), is a 
selective and a full agonist at 7 nAChRs (EC50 = 10 µM). The new generation of these series 
includes the p-chlorbenzamide analog PNU-282987 (9), which is highly selective and a potent 
(EC50 = ~3 µM) 7 nAChR agonist.16 The anabaseine analog GTS-21 (10) is considered a 
prototypical selective partial agonist of the 7 nAChRs (EC50 = 6 µM).16 Unlike ACh, the ACh 
precursor and metabolic product, choline, exerts selective-full agonist activity at 7 nAChRs 
(EC50 = ~1 mM).16,50 
 
e. 7 nACh Receptor Antagonists 
 
The majority of the typical 7 nAChR antagonists are found as naturally occurring 
substances. Two examples of these are the highly selective competitive antagonists: the peptide 
toxin -bungarotoxin (-BTx) (IC50 = 0.005 µM), from the Taiwan banded krait (Bungarus 
multicinctus), and the alkaloid methyllycaconitine (MLA; 11) (Figure 8) (IC50 = 0.0017 µM), 
isolated from Delphinum and Consolida species.16 The selectivity among nAChR subtypes 
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diminished with other antagonists such as dihydro--erythroidine (DHE; 12), d-tubocurarine 
(13), and the peptide toxin -conotoxin (ImI). A 4-oxystilbene derivative, MG624 (14), was 
reported as a highly potent 7 nAChR antagonist over 42 and 11γ nAChRs (IC50 = 0.11 
µM).16  
 
Figure 8. The chemical structures of selective and nonselective 7 nAChR antagonists: 
methyllycaconitine (MLA; 11), dihydro--erythroidine (DHE; 12), d-tubocurarine (13), 
MG624 (14), and memantine (15). 
 
Martin et al.48 reported that MLA (11), a selective 7 nAChR antagonist, is able to play a 
neuroprotective role in AD. The explanation of this action involves the inhibition/desensitization 
action by the 7 nAChR antagonist that is actually a neuroprotective pathway against A1-42-
induced neurotoxicity.48 Another low molecular-weight, selective 7 nAChR antagonist is 
memantine (15) (Figure 8) which is an approved drug for AD.52 Although the approval of 
memantine was based on its ability to antagonize GluR N-methyl-D-aspartate (NMDA) 
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receptors, Banerjee et al.53 considered the inhibitory activity of memantine on 7 nAChRs (IC50 
= 0.34 µM) as the action advantageous to AD therapy.52,54 
 
f. 7 nACh Receptor Allosteric Modulators 
 
 
Allosteric modulators are receptor ligands that interact with different sites (i.e., allosteric 
sites) than the orthosteric site and mediate either or both the binding and the signaling of the 
orthosteric ligand. An allosteric modulation mechanism is widely appreciated and clinically 
founded by the action of benzodiazepines on GABAA receptors.55 Several possible allosteric 
binding sites on nAChRs have been experimentally identified in the ECD and TM domain 
through photoaffinity labeling, epitope mapping, crystallography, and mutagenesis studies.56-59 
This type of receptor ligand is a promising approach for medicinal compounds that presents 
several advantages over classical orthosteric agents (i.e., agonists and antagonists).60,61 The 
saturability of the allosteric site provides better control over an administered agent.60 This 
advantage eliminates any competitive undesired effects (e.g. toxic effect) that might interfere 
with the desired effect. Another advantage is that an allosteric modulator is expected to work 
only at a time when endogenous agonist exists at the orthosteric site.60 By this feature, the 
allosteric modulator effect would vary depending on the nerve tone and the tissue state which, 
apparently, differs from that of the orthosteric ligand that works in a continuous fashion 
irrespective to nerve activity. A third advantage is the receptor subtype selectivity of allosteric 
ligands over classical orthosteric ligands and this is because the orthosteric sites of nAChRs are 
the most conserved region among the receptors subtype.60,61  
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  Allosteric modulators are divided, based on their activity on the receptors, into two main 
classes, positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs). 
Generally, PAMs are allosteric ligands responsible for improving the action of endogenous 
agonists, whereas NAMs are involved in reducing the endogenous agonist’s effect.6,62 
 
1. Positive Allosteric Modulators (PAMs) 
 
From a thermodynamic point of view, PAMs enhance the agonist effect by lowering the 
energy barrier between the receptor’s active and resting states (Figure 6).63 PAMs are believed to 
work either by improving the affinity of an orthosteric ligand due to the conformational changes 
that PAMs generate in the receptors, or by enhancing the coupling between the orthosteric site 
and the area of the receptor responsible for gating.59 In addition, 7 nAChR PAMs are classified 
into two types depending on the desensitization profile of each PAM. For instance, galantamine 
(Gal; 16) (Figure 9) is considered a Type I PAM since it does not affect the desensitization time 
of 7 nAChRs, whereas PNU-120596 (17) prolongs the desensitization time and is classified as 
a Type II PAM.16,64 
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Figure 9. The chemical structures of 7 nAChR PAMs: galantamine (Gal; 16), PNU-120596 
(17), codeine (18), and physostigmine (19). 
 
Some studies have classified compounds like Gal (16), codeine (18), and physostigmine 
(19) (Figure 9) as allosterically-potentiating ligands (APLs) instead of being PAMs.59 Although 
these two classes represent positive modulation in a general sense, some differences related to 
their mechanism and the location at which PAMs and APLs modulate their agonist effects have 
been reported.59 
 
2. Negative Allosteric Modulators (NAMs) 
 
NAMs are allosteric ligands that elevate the energy barrier between the receptor’s active 
and resting states.63 Among efforts for identifying GABAA allosteric modulators, Yoshimura et 
al.55 screened a library of modulators for nAChRs and identified UCI-30002 (20) (Figure 10) as 
one of the first reported highly correlated NAMs of neuronal nAChRs; however, the compound 
was non-selective, and evidence of its action as a NAM at 7 nAChRs was not provided. Our 
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laboratory9,65 reported meta-chlorophenylguanidine (MD-354; 21) as the first subtype-selective 
small molecule to function as a NAM at 7 nAChRs. Abdrakhmanova et al.66 later reported a 
potent selective 7 nAChR NAM, 1,2,3,3a,4,8b-hexahydro-2-benzyl-6-N,N-dimethylamino-1-
methylindeno[1,2,-b]pyrrole (HDMP; 22) (IC50 = 0.07 µM) which is selective for 7 over 42 
and 34 nACh receptors. 
 
 
Figure 10. The chemical structures of non-selective (i.e., UCI-30002 (20)) and selective (i.e., 
meta-chlorophenylguanidine (MD-354; 21) and HDMP (22)) NAMs of 7 nAChRs. 
 
Earlier in our laboratory, the compound MD-354 (21) (Figure 10)  was synthesized 
among several arylguanidine derivatives for an SAR study at 5-HT3 receptors.65 MD-354 
possessed high affinity at 5-HT3 receptors (Ki = 35 nM) and showed affinity for 2B-
adrenoceptors (2B-ARs) nearly equal to that for 5-HT3 receptors.67,68 Although MD-354 does 
not produce antinociceptive effects by itself, it remarkably potentiated an inactive dose of 
clonidine to produce an antinociceptive effect without potentiating clonidine’s sedative effect in 
the mouse tail-flick assay.68,69 In contrast, MD-354 was found to block the antinociceptive 
effects of (-)-nicotine in the mouse tail-flick assay which lead to the conclusion that MD-354 
could not be a general analgesia-enhancing agent and raised the possibility of involvement of 
another mechanism in such effects.9 Further studies showed that MD-354 lacked affinity for the 
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most abundant neuronal nAChRs (i.e., the 42 subtype) and was able to antagonize the 
antinociceptive activity of (-)-nicotine on the second most abundant neuronal nAChRs (i.e., the 
7 subtype) in the tail-flick assay.9 Binding studies that showed that MD-354 lacked affinity for 
7 nAChRs, and the functional data which confirms the inhibition by MD-354 (IC50 = 7.98 µM) 
of 7 nAChRs led to the conclusion that MD-354 allosterically antagonizes 7 nAChRs. MD-
354 was the first small molecule to function as a NAM at 7 nAChRs.9 
 
g. The Role of 7 nAChR in Alzheimer's Disease (AD) 
 
Despite that the molecular details of AD-related memory loss and that the exact role of 
A1-42 and tau protein in cognitive alterations is still not fully understood, a number of studies 
were dedicated to investigate the biological relevance of these to the disease.45 Dziewczapolski et 
al.70 reported a transgenic mouse model of AD that overexpressed the mutated human amyloid 
precursor protein (APP) and was missing the gene responsible for 7 nAChR expression (APP 
7KO). The APP 7KO mice were able to significantly solve the Morris water maze test in a 
better performance time compared with APP mice and APP 7KO mice significantly maintained 
the protection of brain from the reduction of the level of synaptophysin, the presynaptic marker 
that correlates better with the AD progression than A plaques and cell death, in comparison 
with APP mice.70 Zheng et al.71 were able to detect parallel events represented by the activation 
of multiple kinases (e.g., MAPK, glycogen synthase kinase-3 (GSK-3)) which clarified the 
mechanism that links 7 nAChR–A1-42 interactions and tau protein hyperphosphorylation 
(Figure 11). Moreover, Hu et al.8 successfully reported both the phosphorylation of GSK-3 in 
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concordance with the tau protein hyperphosphorylation that resulted from the 7 nAChR–A1-42 
interactions and the attenuation of this undesired effect by 7 nAChR-selective agonists and 
antagonists.  
 
 
Figure 11. The downstream signaling pathways of 7 nAChRs.47 
 
It is also worth mentioning that there is more than one reported mechanism by which 7 
nAChR activation benefits AD patients.  Acute administration of 7 nAChR selective agonists 
has been shown to increase ERK 1/2 and CREB phosphorylation that work as a significant 
signaling pathway in enhancing synaptic plasticity and cognitive function (Figure 11).47 In 
addition, a neuroprotective pathway against the neurotoxicity that resulted from 7 nAChR–A 
interactions, represented by phosphatidylinositol 3-kinase (PI3K), protein kinase Akt, and B-cell 
lymphoma 2 (Bcl2) signaling, has been reported as the consequence of the administration of 7 
nAChR agonists that provide protection(Figure 11).47 
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III. Specific Aims 
 
 
 
The arylguanidine MD-354 (21) was identified by Dukat and co-workers9,65 as the first 
example of a small-molecule negative allosteric modulator (NAM) of 7 nACh receptors. 
Unfortunately, MD-354 also binds at 5-HT3 serotonin receptors with high affinity.  The overall 
purpose of the current project is to decrease or eliminate the affinity of MD-354 at 5-HT3 
receptors while retaining its actions as a NAM of 7 nACh receptors. 
5-HT3 receptor antagonists are used clinically for the treatment of nausea and vomiting 
induced by chemotherapy and radiation.72 Agonists have not been nearly as well investigated. A 
prior goal of our laboratory was to develop the SAR of 5-HT3 receptor agonists in order to 
determine what structural features contribute to their action. PBG (23; 5-HT3 Ki ca 1,200 nM) 
and later mCPBG (26; 5-HT3 Ki ca 18 nM) (Table 1) were examples of the first known 5-HT3 
receptor agonists.65 An initial investigation showed that the entire biguanide moiety of PBG (23) 
and mCPBG (26) is not essential for binding at 5-HT3 receptors and a novel series of compounds 
(i.e., arylguanidines)  was introduced.65,73,74 The functional activity of the new series, represented 
by MD-354 (21), at 5-HT3 receptors was investigated using the shrew emesis assay and 
suggested a partial agonist effect.67 The reasonably high affinity of MD-354 (21) at 5-HT3 
receptors (Ki = 35 nM) led to a structure-affinity investigation and a quantitative structure-
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activity relationship (QSAR) study that covered aryl substitution and the guanidine moiety.65,73,74 
After examining Ki data obtained from the two series (Table 1), it was proposed that 
arylbiguanides and arylguanidines might bind at 5-HT3 receptors in a similar manner.74 This 
study involved application of a widely accepted concept proposed by Portoghese75 in his study 
on analgesics, which stated that “If identically substituted compounds in two different series are 
interacting with receptors in a similar manner, then the quantitative contribution of various 
substituents to the analgesic effect should produce, under steady-state conditions, proportionate 
variations of activity in both series”. 
Table 1. The binding affinities of a number of the same-substituent pairs of arylbiguanides and 
arylguanidines at 5-HT3 receptors.73 
 
 
 
 
 
 
 
R  Ki (nM)   Ki (nM) 
–H 23 1,200.0  31 2,340.0 
4-Me 24 890.0  32 442.0 
2-Cl 25 62.0  33 190.0 
3-Cl 26 18.0  21 35.0 
4-Cl 27 210.0  34 326.0 
3,4-di-Cl 28 12.0  35 3.1 
3,5-di-Cl 29 1.8  36 5.0 
3,4,5-tri-Cl 30 2.7  37 0.7 
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In the arylguanidine series, the introduction of a chloro group at the aryl 3-position (i.e., 
MD-354; 21) showed high binding affinity at 5-HT3 receptors.73 Affinity decreased by the 
replacement of the 3-Cl group of MD-354 with a more electron-withdrawing group such as 3-
CF3 (Ki = 2,440 nM).73 The introduction of a lipophilic methyl group at the 3-position also 
resulted in decreased affinity (Ki = 6,520 nM).73 Follow-up studies on the 3-position using 
Hansch analysis were conducted and identified a correlation between 5-HT3 receptor affinity 
(pKi) and m.74 On the other hand,  the presence of a lipophilic substituent at the 4-position is 
favorable, whereas an electron-withdrawing group at the 4-position (e.g., 4-Cl (Table 1; 27), 4-
CF3) resulted in about a 10-fold increase in affinity.73,74 Using Hansch analysis, there is a better 
correlation between 5-HT3 receptor affinity (pKi) and the  value of 4-position substituents.74 
The 4-position can tolerate lipophilic groups of limited size and this result was also  supported by 
a Comparative Molecular Field Analysis (CoMFA).73,74 
With respect to the guanidine moiety of the arylguanidines, replacement of the aniline 
NH by a methylene group, or replacement of a terminal NH by a carbonyl oxygen atom resulted 
in decreased affinity at 5-HT3 receptors (i.e., 38, 39; Figure 12).65,73 Moreover, the replacement 
of a hydrogen atom at any of the three guanidine nitrogen atoms by a methyl group  resulted in a 
major  decrease, or in a lack, of affinity (i.e., 40, 41, 42; Figure 12).73 Conformationally 
restricted structures also resulted in a decrease or loss of affinity that might be due to a 
disadvantageous binding conformation or lack of bulk tolerance (i.e., 43, 44; Figure 12).73 
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Figure 12. Chemical structures representing different modifications in the guanidine moiety of 
MD-354 (21) and mCPBG (26). 5-HT3 receptor affinity is provided [in brackets] as Ki 
values.65,73 
38 
[Ki = 1,200 nM] 
39 
 [Ki > 10,000 nM] 
40 
[Ki = 6,200 nM] 
41 
[Ki > 10,000 nM] 
42 
[Ki > 10,000 nM] 
43 
[Ki > 10,000 nM] 
44 
[Ki > 10,000 nM] 
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The data obtained from the extensive structure-affinity studies allowed Dukat to 
develop/propose a pharmacophore for arylguanidine interactions with 5-HT3 receptors (Figure 
13).76    
 
 
 
Figure 13. Schematic representation of Dukat’s pharmacophore model for the binding of 
arylguanidines at 5-HT3 receptors. Aromatic ring, adjacent nitrogen atom (N1), and terminal 
amine group form the three major components of the model. Although substituents at the meta 
and para positions of the aromatic ring can increase affinity, steric bulk is less likely to be 
tolerated at N1. (a) Represents the distance between N1 and the adjacent aromatic ring centroid 
which is 2.7 Å. (b) Represents the distance between the terminal amine group and the aromatic 
ring centroid which is 4.5 – 4.9 Å.76 
 
The cross-reactivity of many 7 nAChR and 5-HT3 receptor ligands probably arises from 
the high homology (~ 30%) between the two receptor types, which is considered as the highest 
similarity within the LGIC superfamily.77 As a consequence, MD-354 (21) has been found to act 
as a partial agonist at 5-HT3 receptors (in an in vivo model) and as a NAM at 7 nAChRs (IC50 = 
7.98 µM).9 Moreover, arylguanidine SAR for 5-HT3 receptor binding affinity showed that 
introduction of certain aryl substituents reduces 5-HT3 receptor affinity (i.e., 31, 45, 46; Ki = 
Steric 
Block (?) 
1 
b a 
Substituents 
Tolerated 
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2,340, 2,440, 1600 nM; respectively) and that N-methylation of the aniline nitrogen atom (i.e., 
40) results in a significant reduction in affinity (Ki = 6,200 nM) as well.65,73 The effect of these 
structural changes on the actions of MD-354 (21) at 7 nACh receptors is unknown. Also, there 
is no reason to expect that the guanidine 5-HT3 receptor pharmacophore will be identical with its 
7 nACh receptor pharmacophore. Thus, compounds 31, 40, 45, and 46 will be examined to 
determine the influence of various substituents on NAM action at 7 nACh receptors. Should 
any of these structural alterations be tolerated, this could result in arylguanidines with enhanced 
selectivity as 7 nAChR NAMs. That is, an attempt will be made to take advantages of those 
structural features of arylguanidines already known to be detrimental to 5-HT3 receptor binding; 
incorporation of these substituents into novel arylguanidines might lead to compounds with 
enhanced selectivity as NAMs of nACh receptors.  
 
 
 
Figure 14. Arylguanidines derivatives with different electronic substitution at the 3-position. 5-
HT3 receptor affinity is provided [in brackets] as Ki values.65 
A new series of compounds based on the introduction of different aryl substitution of 40 
will be synthesized and investigated. The chloro group at the 3-position will be replaced with 
different substituents considering the electronic, the lipophilic, and the steric nature of the new 
substituent. The introduction of the other halogens (i.e., -F, -Br, and –I) instead of the chloro 
45 
[Ki = 5,700 nM] 
46 
[Ki = 1,600 nM] 
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group will allow for testing mainly the effect of substituent size variation over a relatively fixed 
electron-withdrawing nature. Furthermore, the replacement of the chloro group with -OCH3 or    
-CH3 groups as electron donating groups, as well as being lipophilic substituents, will explore the 
effect of such modification on activity.  
Another primary goal is to construct and validate a homology model of the ECD of the 
7 nAChR. The significance of such a computational tool in drug design, as an important 
element in medicinal chemistry, is widely appreciated. The constructed model will be used to 
identify the putative allosteric binding site(s) and to determine the interaction mode(s) of 21 and 
40 with 7 nAChRs. Since the 7 nAChR is a homomeric structure, the molecular modeling of 
only two attached subunits (i.e., a dimer) is justified, and should be sufficient, to mimic the 
essential ligand binding domain. The construction will undergo a number of steps and different 
software will be employed. Aligning the amino acid sequence of the targeted portion of the 
protein and the matching portion of the selected template amino-acid sequence will be performed 
using ClustalX 2.0.78 The generation of multiple models lacking validation will be constructed 
using Modeller 9.7. Different docking programs (e.g., GOLD Suite 5.0 and AutoDock 4.1), as 
well as accurate residue orientation processes, should allow for model validation by comparing 
the results with previously published biochemical or crystallographic data. Therefore, the blind 
docking feature of AutoDock 4.1 using Gal (16) as well as the Connolly surface feature of 
SYBYL 8.1 and the hydrophobic interaction (HINT) program will be used to explore the 
possible interaction site(s) at the ECD of 7 nAChRs. GOLD Suite 5.0 will be used for model 
validation through the docking of 7 nAChR agonists (i.e., acetylcholine (1), nicotine (2), EPI 
(5)) and the antagonist MLA (11) and comparing the results with reported crystal structures 
(PDB ID: 2XZ5 , 1UW6, 2BYQ, and 2BYR, respectively).38,79,80 Prior to docking of the studied 
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molecules (i.e., 21, 40), the two compounds will be subject to a systematic search to investigate 
favorable low-energy conformations. The validated ECD models of 7 nAChRs will then be 
used for the new docking studies after specifying the targeted allosteric cavity. The resulting 
complexes of 21 and 40 with the candidate ECD models of 7 nAChRs will provide beneficial 
information that will help in the prediction of required structural modifications to the current 
series. 
General Hypothesis: The structural modifications of MD-354 (21) known to be detrimental for 
5-HT3 receptor binding might provide a possible avenue to enhance 7 nAChR selectivity. In 
fact, there is no a priori reason to believe that what is detrimental for one effect (e.g., 5-HT3 
receptor binding) should be detrimental for a second effect (e.g., 7 nAChR NAM action). 
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IV. Results and Discussion 
 
 
 
A. Synthesis of Initial Arylguanidines 
 
N-(3-Chlorophenyl)-N-methylguanidine hydrochloride (40) was previously prepared in 
our laboratory and the re-synthesis of this compound required three steps described in Scheme 
1.73 The 3-chloroformanilide intermediate 48 was obtained by heating 3-chloroaniline (47)  at 
reflux in an aqueous formic acid solution (95-97%). The formamide group was then reduced 
using borane in tetrahydrofuran and the HCl salt 49 was prepared. An ethanolic solution of 49 
was heated at reflux with cyanamide to give 40. The structure of the known compound was 
confirmed by IR, 1H NMR, and melting point. 
 
Scheme 1.a 
 
 
 
aReagents and conditions: a. Formic acid, reflux; b. BH3•THF, THF, reflux; c. HCl/Et2O; d. 
NH2CN, absolute EtOH, reflux. 
 
a b, c d 
47 48 49 40 
 
 
36 
 
The nitrate salt of m-chlorophenylguanidine (MD-354; 21), hydrochloride salt of 
phenylguanidine (PG; 31); nitrate salt of 3-trifluorophenylguanidine (45) and hydrochloride salt 
of 3-methoxyphenylguanidine (46) were available from previous studies. 
 
B. Biological Data 
The whole-cell configuration of the patch-clamp technique was employed to obtain 
functional data at nAChRs. Rat 7 nAChRs were expressed in stably transfected human 
embryonic kidney (HEK) 293 cells. In addition, the expression of rat 34 nAChRs were 
obtained in HEK 293 cells, whereas a human epithelial cell line (SH-EP1) was used in 
expressing human 42 nAChRs. The latter two receptor types are important to study the 
selectivity of our compounds among nACh receptor subtypes since activation of these receptors 
resulted in serious side effects. For example, activation of 42 nAChRs can be accompanied by 
nausea and vomiting adverse effects in humans.81 On the other hand, activation of 34 nAChRs 
at autonomic ganglia and the CNS is associated with constipation, heart problems and weight 
loss, respectively.82 
 
The project was initiated by the finding that MD-354 (21) does not bind at the orthosteric 
site of 42 (Ki > 10,000 nM) or 7 nACh receptors (Ki > 10,000 nM) but blocks the 
antinociceptive effect of the agonist nicotine in the mouse tail-flick assay.9 Electrophysiological 
studies showed that MD-354 (21) is a noncompetitive 7 nACh receptor antagonist (IC50 = 7.98 
μM).9 Is MD-354 the first small-molecule NAM or is it a channel blocker? The NAM activity of 
MD-354 (21) was confirmed through the elimination of possible competitive antagonism activity 
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since competitive antagonists do not produce inhibition at currents evoked by an ACh-saturated 
concentration (Figure 15A). Also, the elimination of possible channel blocking activity was 
achieved by showing that MD-354 (21) produces a voltage-independent effect at various holding 
potentials whereas channel blockers are voltage-dependent (Figure 15B). 
 
  
Figure 15. The inhibitory effects of MD-354 (21) at 10 μM at 7 nAChRs. (A) The inhibitory 
effects of MD-354 on 7 nAChRs at an EC50 concentration of ACh (i.e., 280 μM) and at a 
saturated concentration of ACh (i.e., 1 mM). (B) The inhibitory effects at various holding 
potentials in the range from -100 to +30 mV. The upper part represents superimposed traces of 
ACh-induced currents in the absence and presence of 21. In the lower part, squares represent the 
maximal amplitude in the absence of 21 plotted versus the corresponding holding potential, 
whereas circles represent the maximal amplitude in the presence of MD-354 (21) at a 
concentration around its IC50 value plotted versus the corresponding holding potential. 
 
(A) (B) 
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 The examination of NAM action of a fixed concentration (i.e., 10 M) of compounds 21, 
31, 40, 45, and 46 at 7 nACh receptors resulted in a different extent of inhibition compared to 
the normalized current evoked by ACh at its EC50 (Figure 16). These results emphasize that the 
structural alterations on MD-354 (21), focusing on analogs with substituents that are detrimental 
to 5-HT3 receptor binding, appear to be tolerated and that the inhibitory activity (i.e., NAM) at 
7 nACh receptors was maintained.  
 
Figure 16. Mean effect of 21, 31, 40, 45, and 46 at 10 M concentration on acetylcholine (ACh; 
EC50 = 280 M) function at 7 nAChRs relative to ACh (normalized current = 1). 
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 Based on the inhibitory activity at 7 nACh receptors of compounds 21, 31, 40, 45, and 
46, IC50 values were obtained (Table 2). The resulting IC50 values showed that when the chloro 
group of MD-354 (21) is removed, potency is decreased (i.e., 31, IC50 = 34.84 M). In the same 
manner, inhibitory potency is reduced when the chloro group of 21 is replaced with the more 
electron withdrawing group –CF3 (i.e., 45; IC50 = 18.46 M). Compound 46 (IC50 = 7.54 M), 
where –OCH3 is an electron donating group at the 3-position of the phenyl ring, shows a potency 
comparable to that of MD-354 (21) at 7 nACh receptors, however, its low affinity at 5-HT3 
receptors makes 46 a more selective 7 nACh receptor inhibitor than 21. A major increase in 
potency at 7 nACh receptors is shown by the N-methyl analog of MD-354 (i.e., 40; IC50 = 1.26 
M) (Figure 17). Compound 40 exhibits more than 1,000-fold shift in selectivity (5-HT3 receptor 
Ki = 6,200 nM) and higher potency at 7 nACh receptors compared to 21 (5-HT3 receptor Ki = 
35 nM).  
Table 2. The IC50 values of MD-354 analogs for attenuation of an ACh-induced response at 7 
nACh receptors, and their affinity for 5-HT3 serotonin receptors. 
 
 
 
 
 
 
 
 
* 7 nAChR IC50 value of 21 reported by Dukat et al.9  
** 5-HT3 receptor Ki values reported by Dukat et al.65,73 
Compound X R 
7 nAChR 
IC50 ± SEM 
(µM) 
5-HT3 R 
Ki 
(nM)** 
21 H Cl 7.98*____ 35  
31 H H 34.84 ± 6.85 2,340  
45 H CF3 18.46 ± 0.42 2,440  
46 H OCH3 7.54 ± 0.74 1,600  
40 CH3 Cl 1.26 ± 0.26 6,200  
 
N
X
NH2
NH
R
 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Functional description of the N-methyl analog of MD-354 (i.e., 40) activity at 7 
neuronal nAChRs. (A) Dose-dependent inhibition of 40 at 7 nAChRs. The Hill equation was 
applied to the curve, and the data were fit. Symbols and bars represent the mean ± SEM. (B) The 
inhibitory effect of 40 at a concentration of 1 μM. Holding potential in (A), and (B) was −80 
mV. 
 
The NAM activity of 40 was confirmed through the elimination of possible competitive 
antagonism activity (Figure 18A) and the elimination of possible channel blocking activity 
(Figure 18B).  
 40 
(A) 
(B) 
 40 
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Figure 18. The inhibitory effects of 40 at 1 μM at 7 nAChRs. (A) The inhibitory effects of 40 
on 7 nAChRs at an EC50 concentration of ACh (i.e., 280 μM) and at a saturated concentration 
of ACh (i.e., 1 mM). (B) The inhibitory effects at various holding potentials in the range from     
-100 to +60 mV. The upper part represents superimposed traces of the ACh-induced currents in 
the absence and presence of 40. In the lower part, squares represent the maximal amplitude in the 
absence of 40 plotted versus the corresponding holding potential, whereas circles represent the 
maximal amplitude in the presence of 40 at a concentration around its IC50 value plotted versus 
the corresponding holding potential. 
 
The activity of 21, 31, 40, 45, and 46 at a fixed concentration of 10 M at 34 nACh 
receptors was investigated to test the selectivity of these compounds among nAChR subtypes 
(Figure 19). MD-354 (21) showed the lack of activity at 10 M concentration on ACh-induced 
(A) (B) 
 40  40 
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currents at 34 nAChRs relative to ACh EC50 = 100 M (Figure 20), whereas 31 and 40 
slightly attenuated the ACh (EC50 = 100 μM)-evoked currents. Compounds 45 and 46 reduced 
the current of ACh to a different extent.   
 
 
 
 
Figure 19. Mean effect of 21, 31, 40, 45 and 46 at 10 M concentration on acetylcholine (ACh) 
function at 34 nAChRs relative to ACh EC50 = 100 M (normalized current = 1). 
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Figure 20. The inhibitory effect of MD-354 (21) at 10 M concentration in representative cell 
expressing 34 nAChRs. Holding potential for these recordings was - 80 mV. 
 
 MD-354 (21) neither displayed affinity (Ki > 10,000 nM) nor possessed functional 
activity at 42 nAChRs. The activity of 21 as well as 40 at 42 was investigated as part of the 
selectivity test of these compounds among nAChR subtypes (Figure 21). Both compounds at 
concentrations comparable to the IC50 for 7 neuronal nACh receptors showed no activity on 
ACh induced-current (EC50 = 20 M) at 42 nACh receptors. In addition, both compounds 
were examined for their agonist activity at 42 nACh receptors at their IC50 concentration and 
failed to mimic ACh actions.  
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Figure 21. Effect of MD-354 (21) and 40 on 42 nAChRs. (A) Effect of ACh at EC50 = 20 M 
and saturated concentration = 1 mM. (B) Effect of MD-354 (21) on ACh (EC50 = 20 M) 
evoked-current and by itself at 42 nAChRs. (C) Effect of ACh (EC50 = 20 M) alone and 
effect of ACh at EC50 = 20 M accompanied by 10 M of 40. (D) Effect of 40 at 1 M on ACh 
(EC50 = 20 M) evoked-current and by itself at 42 nAChRs. Holding potential for these 
recordings was - 80 mV. 
 
(A) (B) 
 40        
 40        
 40        
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The biological data obtained above provide essential information on some of the 
compounds of interest. It also formed the bases for the need of further investigations to 
determine and optimize the required structural features of the small-molecule NAMs at 7 
neuronal nAChRs.  
 
C. Compound Optimization 
Considering the functional data from MD-354 (21) and its N-methyl analog 40, a new 
series of compounds was synthesized. The chloro group at the 3-position of N-(3-chlorophenyl)-
N-methylguanidine (40) was replaced with a number of substituents considering the electronic, 
the lipophilic, and the steric nature of the new substituent (Table 3). In addition, the activity of 
any new modification at 7 nACh receptors will be compared to that determined for the same 
modification in the MD-354 series to test if parallel structural modification would result in 
parallel change in activity which might suggest whether or not the two series bind at the same 
manner (Table 3). The introduction of other halogen atoms (i.e., -F, -Br, and –I) at the 3-position 
will allow for testing mainly the effect of substituent size variation over a relatively fixed range 
of electron-withdrawing effects. A recent study on a number of structurally related 7 nACh 
receptor modulators described the diverse impact of different halogen atoms at the same ring 
position on the compound pharmacological properties.83 That is, the replacement of a bromine 
atom in the para position of an aromatic ring of an allosteric agonist with an iodine atom or a 
chlorine atom resulted in PAM activity with different levels of desensitization, activation rates, 
and inactivation rates, whereas a fluorine atom at the same position antagonized the allosteric 
agonist effect of the para-bromo compound. Furthermore, replacement of the chloro group with -
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CH3 or -OCH3 groups as electron donating groups, as well as being lipophilic substituents, will 
explore the effect of such modification on activity. 
 
       
  
 
 
 
a  and m aromatic R substituent constants reported by Hansch et al.84 
 
The N-methyl-N-phenylguanidines (with the exception of 53) were synthesized as 
described in Scheme 2. The targeted compounds were unknown except for N-methyl-N-
phenylguanidine hydrochloride (50).85 The process of synthesis consisted of a one-step reaction  
for compounds N-methyl-N-phenylguanidine hydrochloride (50), N-(3-bromophenyl)-N-
methylguanidine hydrochloride (51), N-(3-fluorophenyl)-N-methylguanidine hydrochloride (52), 
Compound  R a m a  Compound 
40  Cl 0.71 0.37  21 
50  H 0.00 0.00  31 
51  Br 0.86 0.39  56 
52  F 0.14 0.34  57 
53  I 1.12 0.35  58 
54  CH3 0.56 -0.07  59 
55  OCH3 -0.02 0.12  46 
Table 3. Structural representation and substituent constants of the new N-methyl series and the 
MD-354 series of arylguanidines. 
 
N
H3C NH2
NH
R
HN NH2
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R
MD-354  
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N-methyl 
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and N-(3-methoxyphenyl)-N-methylguanidine hydrochloride (55) where the appropriate anilines 
(i.e., 60 – 64; Scheme 2) were heated at reflux with cyanamide in absolute ethanol. The 
hydrochloride salt of N-(3-methylphenyl)-N-methylguanidine (54) was converted to the nitrate 
salt with ammonium nitrate. The structure of N-methyl-N-phenylguanidine hydrochloride (50) 
was  confirmed by IR, 1H NMR, and melting point, whereas the structures of the remaining 
compounds were confirmed by IR spectrometry, 1H NMR spectrometry, and elemental analysis 
for C, H, N. 
 
Scheme 2.a 
 
 
 
 
  
 
 
 
 
 
 
aReagents and conditions: a. i) NH2CN, EtOH, reflux; ii) (only to 54) NH4NO3, H2O. 
 
N
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-CH3 HNO3 54 
-OCH3 HCl 55 
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N-(3-Iodophenyl)-N-methylguanidine hydrochloride (53) was prepared as described in 
Scheme 3. This was an unknown compound at the time of synthesis, but was prepared according 
to a literature procedure for a similar compound.85,86 The first step of this reaction is a one-pot 
procedure in which a mixture of 3-iodoaniline (65) and trimethyl orthoformate (66) was heated at 
120 C in the presence of sulfuric acid. In a rearrangement step, the mixture was then heated at 
170 C that resulted in an N-methylformanilide intermediate. 3-Iodo-N-methylaniline (67) was 
obtained by heating the N-methylformanilide intermediate at reflux with an aqueous solution of 
HCl. The final step was performed by heating the ethanolic solution of 67 at reflux with 
cyanamide to give 53. The desired compound was confirmed by IR spectrometry, 1H NMR 
spectrometry, and elemental analysis for C, H, N. 
  
Scheme 3.a 
N
H3C NH2
NH
HCl
NH
H3C
HCl
I
NH2
II
O O
O CH3H3C
H3C  
 
aReagents and conditions: a. Sulfuric acid (concentrated solution), heat (120 C); b. Heat (170 
C); c. HCl, H2O, reflux; d. NaOH, H2O; e. HCl/absolute EtOH; f. NH2CN, absolute EtOH, 
reflux. 
 
The necessity of introducing the N-methyl series was also to test whether or not the two 
series interact with 7 nACh receptors in a similar manner depending in the fold difference in 
biological data obtained. For this reason, the inhibitory activity of 50 at 7 nACh receptors was 
a, b, c, d, e f 
65 66 67 53 
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tested and together with the inhibitory activity of compound 40 from the new N-methyl series 
were selected to be compared with that of 21 and 31 of the MD-354 series (Figure 22) (Table 4).  
 
 
Figure 22. Mean effect of 21, 31, 40, and 50 at 10 M concentration on acetylcholine (ACh; 
EC50 = 280 M) function at 7 nAChRs relative to ACh (normalized current = 1). 
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Table 4. The IC50 values of 21, 31, 40, and 50 for 7 nACh receptors. 
 
 
 
 
* 7 nAChR IC50 value of 21 reported by Dukat et al.9 
 
The functional data on two compounds of each series (i.e., 21 and 31 of MD-354 series, 
and 40 and 50 of the new N-methyl series) revealed the inhibitory activity of these compounds at 
7 nACh receptors. The number of compounds tested here might not be sufficient to decide that 
the N-methyl series binds in the same manner with 7 nAChRs as MD-354 series. The 
possibility that the N-methyl series might bind to a different allosteric site than that of the MD-
354 series, or the N-methyl series could bind to the same allosteric site as that of the MD-354 
series remains to be considered.  
 Data for compounds 51, 52, 54, and 55 were not available at the time this thesis was 
being written. Studies are currently underway. 
 
 
 
Compound IC50 ± SEM (µM) Compound 
IC50 ± SEM 
(µM) 
21 7.98*____ 40 1.26 ± 0.26 
31 34.84 ± 6.85 50 30.81 ± 2.13 
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D. Molecular Modeling 
All the previous functional data were used in the molecular modeling studies to speculate 
the possible location of the binding site as well as the mode of interaction by which small-
molecule NAMs exerts their effect at 7 nACh receptors. 
1. Alignment of Sequences and Model Construction 
 
 
The sequences adopted in this project were obtained from the Protein Knowledgebase 
(UniProtKB). Alignment of the ECD portion of three nAChR species (i.e., human 7 nAChR, rat 
7 nAChR, and mouse 1 nAChR) was performed using the ClustalX program as an initial step 
toward the construction of the human 7 nAChR ECD model (Figure 23). An alignment was 
established to identify and match conserved residues between the human 7 nAChR the template 
mouse 1 nAChR ECDs.  
 
Important regions in the aligned sequences were identified including the loops A, B, C, 
D, E, and F that primarily formed the orthosteric binding sites in these receptors. Other important 
amino acids including Trp171, Tyr115, Tyr217, the two cysteine residues (i.e., Cys150 and 
Cys164) forming the disulfide bond characterizing the Cys-loop, and the adjacent two cysteine 
residues (Cys212 and Cys213) forming the disulfide bond at the C loop were also matched. 
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Figure 23. Sequence alignment of the ECD portion of three nAChR species. The asterisks (*) 
indicate conserved amino acids, whereas the colons (:) and periods (.) indicate strongly and 
weakly conserved amino acids, respectively. The main loops in the ECD are represented by the 
colored lines. 
 
 
The construction of the homology model of the human 7 nAChR ECD was based on the 
crystal structure of the ECD of the mouse 1 nAChR subunit bound to -bungarotoxin at 1.94 Å 
resolution (PDB ID 2QC1).32 The template shares a high degree of homology with the human 7 
nACh receptor subunit (38%) compared with the AChBP of Lymnaea stagnalis (24%).87 
However, a recent study revealed the crystal structure of the ECD of a receptor chimera 
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constructed from the human 7 nAChR and the AChBP of Lymnaea stagnalis.88 The new crystal 
structure shares 64% sequence identity with the native 7 nACh receptor ECD.  
 
The three-dimensional structures of 100 models of human 7 nAChR ECDs were built 
by homology modeling in the form of one monomer using Modeller 9.7. Script was used to 
rejoin disulfide bonds and to form dimers by copying each model and merging each copy to the 
original monomer based on dimers available from the AChBP crystal structure. Since 7 nACh 
receptors are homomeric and the orthosteric binding site is located between each two subunits, 
dimer formation provided the essential part of the ECD for the molecular modeling study.  
 
2. Structural Validation 
 
As part of the model validation procedure, known 7 nACh receptor agonists (ACh (1), 
nicotine (2), and epibatidine (5)) were docked in a directed docking experiment (i.e., 10 Å from 
the C of Trp171) and it was verified that the ligands bind properly to the orthosteric binding 
site. GOLD docking was able to place ACh (1), nicotine (2), and epibatidine (5) in similar 
locants as reported in crystal structures.38,79,80 A common model amongst 100 with all three 
ligands docked was selected as the candidate model for orthosteric agonists. The resultant 
docking solutions were subjected to an energy minimization step that was constructed using the 
Tripos Force Field (Gasteiger–Hückel charges, distance-dependent dielectric constant = 4.0). 
The stereochemistry of the candidate 7 ECD model was examined by PROCHECK analysis 
and a Ramachandran plot of the model was generated (Figure 24). In the Ramachandran plot, 
amino acids falling in the red region are most favored, in the yellow region are additionally 
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allowed, in lighter yellow regions are generously allowed, and in the white region are 
disallowed. The Ramachandran plot showed that 93.6% of the residues were in the most favored 
regions, 5.8% of residues were in additionally allowed regions, 0.3% of residues were in the 
generously allowed regions, and only 0.3% of the residues were in disallowed regions. Glu120 
appeared in the disallowed region and is located in the lining face of the receptor channel in an 
area away from the orthosteric binding site. The amino acid residues’ bond angles, bond lengths, 
and torsion angles were analyzed by the ProTable module in SYBYL. The docking solutions 
were analyzed based on crystal structures of those agonists in complex with AChBPs (PDB ID: 
2XZ5 , 1UW6, and 2BYQ).38,79,80 Selected residues from the orthosteric binding site of the 7 
nAChR ECD model and the AChBP crystal structure were used for alignment and the root-
mean-square deviation (RMSD) was examined to test the validation of the candidate model for 
each agonist. Amino acids at the C loop were not included since the constructed models were 
based on the crystal structure of the mouse 1 nAChR ECD subunit bound to the antagonist -
bungarotoxin (i.e., closed state) where extension of the loop C causes difficulty in mimicking the 
loop orientation in the generated models. 
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Figure 24. A Ramachandran plot of the candidate 7 nAChR ECD model for agonists. Phi and 
psi represent the backbone conformation angles of the amino acids. 
 
ACh (1)-docked poses were visually inspected taking into consideration the GoldScore 
fitness function to select the final solution. The backbone residues involved in the binding pocket 
were aligned to that of the corresponding residues in the crystal structure of the AChBP (PDB 
ID: 2XZ5) and the calculated RMSD was 0.6 Å (Table 5). Similar interactions of ACh in both 
the candidate model and the AChBP crystal structure were observed which includes a cation- 
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interaction between the quaternary amine group in ACh and the conserved Trp171 residue from 
the B loop (Figure 25). 
 
Table 5. Amino acids from the ACh 7 nAChR ECD model and the AChBP crystal structure 
that are involved in the orthosteric binding site that were used in alignment and RMSD 
calculations. 
 
7 nAChR ECD model AChBP* 
Principal or (+)  
face 
Complementary or (-) 
face 
Principal or (+)  
Face 
Complementary or (-) 
face 
Tyr115 Gln139 Tyr91 Met114 
Trp171 Leu141 Trp145 Ile116 
Ser172  Val146  
Tyr210  Tyr186  
Cys212  Cys188  
Cys213  Cys189  
Tyr217  Tyr193  
 
* AChBP crystal structure reported by Brams et al.79 
 
Excluded 
C loop 
residues in 
RMSD 
calculation
s 
Excluded 
C loop 
residues in 
RMSD 
calculation
s 
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Figure 25. The binding mode of docked ACh in the 7 nAChR ECD model (rendered as green 
ball-and-stick model) aligned to the AChBP crystal structure in complex with ACh (rendered as 
cyan ball-and-stick model). Residues labeled in black represent the principal face, whereas 
residues labeled in blue represent the complementary face. 
 
 
Nicotine (2)-docked poses were visually inspected taking into consideration the 
GoldScore fitness function to select the final solution. The backbone of residues involved in the 
binding pocket were aligned with that of the corresponding residues in the crystal structure of the 
Arg101 
Tyr217 
Tyr210 
Tyr115 
Trp171 
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AChBP (PDB ID: 1UW6) and the calculated RMSD was 0.5 Å (Table 6). Similar interactions of 
nicotine in both the candidate model and the AChBP crystal structure were observed; however, a 
cation- interaction between the cationic amine group in the pyrrolidine ring of nicotine and the 
conserved Trp171 from the B loop in the crystal structure was not observed in the docked model 
(Figure 26). 
 
Table 6. Amino acids from the nicotine 7 nAChR ECD model and the AChBP crystal structure 
that are involved in the orthosteric binding site used in alignment and RMSD calculations. 
 
7 nAChR ECD model AChBP* 
Principal or (+)  
face 
Complementary or (-) 
face 
Principal or (+)  
face 
Complementary or (-) 
face 
Tyr115 Trp77 Tyr98 Trp53 
Trp171 Leu141 Trp143 Met114 
Tyr210  Tyr185  
Cys212  Cys187  
Cys213  Cys188  
Tyr217  Tyr192  
 
* AChBP crystal structure reported by Celie et al.80 
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Figure 26. The binding mode of docked nicotine in the 7 nAChR ECD model (rendered as 
green ball-and-stick model) aligned to the AChBP crystal structure in complex with nicotine 
(rendered as cyan ball-and-stick model). Residues labeled in black represent the principal face, 
whereas residues labeled in blue represent the complementary face. 
 
 
The docked poses of epibatidine (5) in the candidate model were subjected to the process 
of inspection and evaluation to select the final solution. The backbone residues involved in the 
binding pocket were aligned to that of the corresponding residues in the crystal structure of 
Arg101 
Tyr217 
Tyr210 
Tyr115 
Trp171 
Trp177 
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AChBP and the calculated RMSD was 0.8 Å (Table 7). Similar interactions of epibatidine in 
both the candidate model and the AChBP crystal structure were observed which included a 
cation- interaction between the cationic amine group in the azabicyclo[2.2.1]heptane system of 
epibatidine and the conserved Trp171 from the loop B (Figure 27). 
 
Table 7. Amino acids from the epibatidine 7 nAChR ECD model and the AChBP crystal 
structure that are involved in the orthosteric binding site used in alignment and RMSD 
calculations. 
 
7 nAChR ECD model AChBP* 
Principal or (+)  
face 
Complementary or (-) 
face 
Principal or (+)  
face 
Complementary or (-) 
face 
Tyr115 Gln139 Tyr91 Met114 
Trp171 Leu141 Trp145 Ile116 
Ser172  Val146  
Tyr210  Tyr186  
Cys212  Cys188  
Cys213  Cys189  
Tyr217  Tyr193  
 
* AChBP crystal structure reported by Hansen et al.38 
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Figure 27. The binding mode of docked epibatidine in the 7 nAChR ECD model (rendered as 
green ball-and-stick model) aligned to the AChBP crystal structure in complex with epibatidine 
(rendered as cyan ball-and-stick model). Residues labeled in black represent the principal face, 
whereas residue labeled in blue represent the complementary face. 
 
Based on the docking poses of the agonists (ACh (1), nicotine (2), and epibatidine (5)), 
models generated showed docking results that are sufficiently close to the crystal structural 
findings. Then validation targeting the closed state of the receptor using the 7 nAChR 
antagonist was constructed. The 7 nAChR antagonist MLA (11) was docked to the original 100 
models and the docked poses were visually inspected taking into consideration the GoldScore 
fitness function to select the final model and docking solution to be compared to the crystal 
Arg101 
Tyr217 
Tyr210 
Tyr115 
Trp171 
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structure of MLA in complex with the AChBP.38 The MLA structure in the candidate model was 
aligned to that of the crystal structure of the AChBP (PDB ID: 2BYR) and the calculated RMSD 
was 1.0 Å (Figure 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. The binding mode of docked MLA in the 7 nAChR ECD model (rendered as green 
ball-and-stick model) aligned to the AChBP crystal structure in complex with MLA (rendered as 
cyan ball-and-stick model). The high degree of alignment between the two MLA molecules can 
be seen. Interacting residues are primarily formed by the principal face. 
Cys212 
Tyr217 
Tyr210 
Tyr115 
Trp171 
Asp219 
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The high degree of alignment between MLA in the candidate 7 nAChR ECD model and 
the MLA in AChBP crystal structure was expected since the template ECD of the mouse 1 
nAChR subunit was crystallized with the antagonist -bungarotoxin (i.e., closed state). A 
Ramachandran plot was generated and the plot showed that 79.4% of the residues were in most 
favored regions, 23.1% of residues were in the additionally allowed regions, 0.5% of residues 
were in the generously allowed regions, and none of the residues were in disallowed regions 
(Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
Figure 29. A Ramachandran plot of the candidate 7 ECD nAChR model for antagonists. Phi 
and psi angles represent the backbone conformation of the amino acids. 
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After validation of the 7 ECD nACh receptor models in the open and closed state, the 
process of exploring and targeting the allosteric sites were initiated in an effort to explain the 
activity of MD-354 (21) as well as 40 as NAMs at 7 nACh receptors. The procedure started 
with allosteric site identification step to speculate the putative binding site.  
 
3. Identification of Allosteric Binding Sites 
 
The identification of five initial cavities was obtained through the blind docking feature 
of AutoDock 4.1 using Gal (16) as well as the Connolly surface feature of SYBYL 8.1 and a 
systematic cavity search using the hydrophobic interaction (HINT) program. Two out of the five 
explored cavities showed a possibility of accommodating small-molecule NAMs as interaction 
site(s) at the ECD of 7 nAChRs and these were supported by empirical data.56,59 The first cavity 
(Figure 30) is characterized by a Thr197 (chimeric chicken 7/mouse 5-HT3 receptor-channel 
complex) mutagenesis study and the residue is located right below the orthosteric binding site.59 
The second cavity (Figure 31) is characterized by Lys125 (Torpedo nAChR) in a photoaffinity 
labeling study as the target of allosteric potentiating ligands (APLs).56 Amino acid residues 
lining both sites were identified (Table 8), and were in agreement with the previous reported 
residues lining these two putative allosteric sites by Luttmann et al.89 
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Table 8. List of amino acid residues lining allosteric sites 1 and 2. 
 Allosteric Site 1 Allosteric Site 2 
Principal or (+)  
face 
Tyr115, Asn116, Ser117, 
Ser148, Ser149, Cys150, 
Cys164, Lys165, Leu166, 
Lys167, Tyr218, Thr221a. 
Met63, Asp64, Asp66, Asn69, 
Val71, Thr73, Asn75, 
Asp119, Glu120, Asp123, 
Ile145, Lys171b. 
Complementary or (-)  
face 
Leu60, Gln61, Asn75, 
Gly189, Tyr190, Ile191. 
Met63, Asp64. 
 
a Thr221 corresponds to the reported Thr197 in the mutagenesis study.59 
b Lys171 corresponds to the reported Lys125 in the photoaffinity labeling study.56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. The location of the first identified allosteric cavity (yellow) below the orthosteric site 
(blue) in the ECD model of the 7 nAChR. 
Orthosteric 
site 
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Figure 31. The location of the second identified allosteric cavity (red) on the internal side of the 
receptor channel in the ECD model of the 7 nAChR. 
The functional data differences between MD-354 (21) and 40 could arise either from the 
differences in the binding site or in the mode of action of the molecule. To investigate that, 
structural preparation was necessary to determine the favorable low-energy conformation of both 
compounds. 
 
4. Structural Preparation for Docking 
 
Earlier in our laboratory, a computational structural investigation on MD-354 (21) 
resulted in four rotameric conformations.90 The same systematic search algorithm was applied 
(semi-empirical molecular orbital AM1 calculations) to identify possible low-energy rotamers of 
40 (Figure 32). Four low-energy rotamers of 40 were identified and computationally prepared 
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for docking; (+/-) synclinial (sc), (+/-) anticlinial (ac) (Figure 32). Each rotamer of MD-354 (21) 
and 40 was docked in allosteric site 1 and 2 to cover the possible conformations that might 
interact with 7 nACh receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Low-energy rotamer identification of 40. A. Calculated energy associated with 
different torsion angels of the rotatable bond. B. Structural representation of the four identified 
rotamers, (+/-) synclinial (sc), (+/-) anticlinial (ac). 
+ sc + ac - ac - sc 
+ sc + ac - ac - sc 
(A) 
(B) 
30 rotation 30 rotation 
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 Before docking 21 and 40 at the constructed 7 ECD nACh receptor models, an 
argument about two possible ways for the docking of rotamers was analyzed. The first way is to 
use either the validated agonist model or the validated antagonist model for docking since the 
two models have a high probability to mimic the exact loop orientation of the receptor ECD at 
the open and closed state, respectively. The second way is to utilize the original 100 models for 
docking to predict the candidate model of each allosteric site using the same standard of high 
GoldScore fitness function value as well as visual evaluation that was applied in the previous 
validation step. The latter was selected since the previous validation for the agonist and 
antagonist models is, in fact, a validation for the orthosteric binding site region and not for the 
other model regions. 
 
5. Docking Solutions 
 
Docking solutions, performed by GOLD Suite 5.0, were analyzed by SYBYL 8.1. 
Docking of both 21 and 40 showed different possible poses that were visually inspected taking 
into consideration the GoldScore fitness function to select the final solution. Energy 
minimization was carried out using the Tripos Force Field (Gasteiger-Hückel charges, distance-
dependent dielectric constant = 4.0).  
 
Plausible binding modes for 21 and 40 in allosteric site 1 (characterized by a Thr221) 
revealed two main clusters (Figure 33). The rotamers of 21 appear to utilize the same binding 
mode (N1 and N2 form ionic hydrogen bonds with Asp219; hydrophobic interactions exist 
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between the phenyl ring and Thr221) with alternate locations of the chloro group (possible 
hydrophobic interaction with the aliphatic chain of Lys204). In contrast, N2 and N3 of 40 form 
ionic hydrogen bonds with Asp219 as the major difference detected at this allosteric site. N3 
shows further a hydrogen bond interaction with Thr221. In addition to a pose similar to 21, 40 
utilizes a binding mode with the phenyl ring oriented in a different direction; that is, the chloro 
group of 40 displays Van der Waals interactions with Arg208.  The introduction of the N1-
methyl group to MD-354 (i.e., 40) appears as the key difference in activity since the methyl 
group on N1 precludes ionic hydrogen bonding with Asp219.  Furthermore, differences in 
interacting residues might provide another explanation of the functional activity differences 
(Table 9). 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Binding modes of 21 (A) and 40 (B) at allosteric site 1. Residues labeled in black 
represent the principal face. 
(B) 
(A) 
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The stereochemistry of the candidate 7 ECD model for allosteric site 1 was examined 
by PROCHECK analysis. A Ramachandran plot was generated and the plot showed that 74.7% 
of the residues were in the most favored regions, 24.4% of residues were in the additionally 
allowed regions, 0.3% of residues were in the generously allowed regions, and 0.6% of residues 
were in the disallowed regions (Figure 34). Arg121 from the principal subunit and Glu120 from 
the complementary subunit shown in the disallowed region are located in the lining face of the 
receptor channel in an area distant from the binding site. 
 
Table 9. List of amino acid residues at allosteric site 1 interacting with 21 and 40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MD-354 (21) 40 
N1 Asp219 – 
N2 Asp219  
Asp219, D119 
 
N3 – Asp219, Thr221  
Phenyl Thr221, Lys204  
Thr221, Lys204 
 
-Cl Lys204 Lys204, Arg208 
 
N NH2
N
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N
CH3N
N
Asp Asp
Cl
H
H
H
H
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Figure 34. A Ramachandran plot of the candidate 7 ECD nAChR model for allosteric site 1. 
Phi and psi represent the backbone conformations of the amino acids. 
 
Both 21 and 40 were docked in allosteric site 2 (characterized by Lys147) and they utilize 
three similar binding modes (Figures 35; orange, purple and white orientations). Two of these 
(orange and purple) exhibit guanidine moieties whose N2 and N3 atoms interact with Asp64 and 
Asp119, and the phenyl groups are oriented in opposite directions. One of the possible modes of 
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interaction (white orientation), located above the previous two, exhibit guanidinium interactions 
with Glu120 and Asp123 and the phenyl group is oriented toward Ile145. Furthermore, one of 
the rotamers of 21 has a distinctive binding mode (green orientation) wherein the guanidinium 
group also interacts with Glu120 and Asp123, but the phenyl group is oriented toward Glu120. 
The guanidine moiety in each of these binding modes shows an ionic hydrogen bond interaction 
with one or two carboxyl groups whereas the phenyl groups engage in hydrophobic interactions 
with a number of amino acid residues including the experimentally-implicated Lys147.  
 
 Although four clusters of docking solutions were observed in MD-354 (21) binding 
orientations, three docking solution clusters were observed for the N-methyl analog (40) (Figure 
35). The introduction of an N1-methyl group to MD-354 (i.e., 40) allows for the disfavoring of 
one of the docking clusters and appears to be the key difference in the allosteric site 2, assuming 
both 20 and 40 bind to the same site. If all of the compounds bind at allosteric site 2, different 
interacting residues could represent the key point that explains the functional data differences 
between 21 and 40 (Table 10). 
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Figure 35. Binding modes of 21 (A) and 40 (B) at allosteric site 2. Residues labeled in black 
represent the principal face, whereas residues labeled in blue represent the complementary face. 
 
 
Asp123
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Met63 
Met63 
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Table 10. List of amino acid residues at allosteric site 2 interacting with 21 and 40. 
 
 
 
 
 
 
 
 
 
 
 
 
The stereochemistry of the candidate 7 nAChR ECD model for allosteric site 2 was 
examined by PROCHECK analysis and the generated Ramachandran plot was analyzed. The 
plot showed that 72.5% of the residues were in the most favored regions, 26.7% of residues were 
in the additionally allowed regions, and, like with the previous model, 0.3% of residues were in 
the generously allowed regions, and 0.6% of residues were in the disallowed regions (Figure 36). 
Arg121 and Glu120, amino acids from the principal and the complementary subunit, 
respectively, were in the disallowed region; however, the two residues’ relative location are in 
areas distant from the binding site. 
 MD-354 (21) 40 
N1 – – 
N2 Asp64, Asp119 Glu120, Asp123 
Asp64, Asp119 
Glu120, Asp123 
N3 Asp64, Asp119 Glu120, Asp123 
Asp64, Asp119 
Glu120, Asp123 
Phenyl 
Ile145, Glu120 
Asp66, Met63 
Lys147 
Ile145, Asp66 
Met63, Lys147 
-Cl Ile145 Asp66 
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Figure 36. A Ramachandran plot of the candidate 7 ECD nAChR model for allosteric site 2. 
Phi and psi represent the backbone conformation of the amino acids. 
 
Although the differences in the pose of interactions of 21 and 40 at the 7 nACh 
receptor’s putative allosteric sites might explain the differences in their biological effect, it is 
also possible that each molecule interacts with distinct allosteric sites. The two models proposed 
here might answer the question about the possible ways by which better 7 nAChR negative 
allosterism is achieved by the introduction of a methyl group to MD-354 (i.e., 40), if we assume 
the compounds act at the ECD.  
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V. Conclusions 
 
 
 
A number of MD-354 analogs were synthesized and evaluated for their activity as 
allosteric modulators of 7 nACh receptors and their ability to bind at 5-HT3 serotonin receptors. 
That is, MD-354 is the first example of a small-molecule allosteric modulator of 7 nAChRs. 
However, MD-354 binds with high affinity at 5-HT3 serotonin receptors and, indeed, was 
initially developed as a 5-HT3 receptor agonist. The focus of this investigation was on those 
structural features of arylguanidines already known to be detrimental to 5-HT3 receptor binding. 
The incorporation of these substituents into novel arylguanidines led to compounds with 
enhanced selectivity as NAMs of 7 nACh receptors. We showed that the two actions can be 
divorced and that removing the structural feature required for 5-HT3 binding also results in an 
enhancement of 7 nACh receptor NAM potency. Among the compounds tested, the N-methyl 
analog of MD-354 (i.e., 40) shows more than 5,000-fold higher selectivity (i.e., 5-HT3 receptor 
Ki = 6,200 nM) and higher potency at 7 nACh receptors (i.e., IC50 = 1.26 M) compared to 
MD-354 (21) (i.e., 5-HT3 receptor Ki = 35 nM; IC50 = 7.98 μM).  
 
A new N-methyl series was synthesized and the purpose was to optimize their inhibitory 
effect at 7 nACh receptors. The modifications included the replacement of the 3-position 
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substituent of N-methyl MD-354 with several other substituents considering the electronic, 
lipophilic, and steric character of the substituent. Halogen atoms (i.e., -F, -Br, and –I in 52, 51, 
and 53, respectively) were introduced at the 3-position mainly to test the effect of substituent size 
variation over a relatively fixed range of electron-withdrawing effects and/or possible change in 
pharmacological profile of the new molecules. 
 
Another reason for synthesizing the new N-methyl series was to investigate whether or 
not both series bind in the same manner. The functional data on two compounds from each series 
(i.e., 21 and 31 of the MD-354 series, and 40 and 50 of the N-methyl series) revealed different 
relative potencies. The remaining compounds are still under investigation. 
 
One hundred homology models of 7 nAChR ECD were generated based on the crystal 
structure of ECD of the mouse 1 nAChR subunit bound to -bungarotoxin at 1.94 Å resolution 
(PDB ID 2QC1). At the validation step, two models were able to successfully predict the 
receptor interactions with agonists (i.e., ACh (1), nicotine (2), and EPI (5)) and the antagonist 
MLA (11) which might represent the open and the close states of the ECD of 7 nACh 
receptors, respectively. High fitness score of GOLD Suite 5.0 as well as the visualized residue 
orientations allowed for model validation by comparing the results with previously published 
biochemical and crystallographic data. The resultant automatic alignment showed good overlap 
within the conserved regions at the orthosteric site residues, except for the C loop of the 
agonists’ model. 
 
 
 
79 
 
The exploration of possible allosteric sites at the ECD of 7 nACh receptors resulted in 
the identification of two potential binding sites. The first putative allosteric site is located 
beneath the orthosteric site and characterized by Thr221. The second putative allosteric site lines 
the channel and is characterized by Lys147. Both identified sites are in agreement with 
previously reported allosteric binding sites of 7 nACh receptor APLs. The 7 nACh receptor 
NAMs MD-354 (21) and 40 were computationally prepared and four low-energy rotamers of 
each were identified. Focusing on docking solutions of MD-354 (21) and 40 at these two 
identified allosteric sites was important to speculate the structural aspects that provide the major 
potency improvement at 7 nACh receptors. However, additional studies need to be done to 
explore the TM domain of the receptor.  
 
The resultant docking poses were analyzed to detect the effect of the introduction of an 
N-methyl group on MD-354 binding. A high fitness score of GOLD Suite 5.0 and the visualized 
ligand-receptor interactions allowed for model validation. At allosteric site 1, the introduction of 
the N1-methyl group to MD-354 (i.e., 40) prevents ionic hydrogen bonding with Asp219. At 
allosteric site 2, MD-354 (21) showed an additional binding orientation that is distinctive from 
the common three docking solution clusters that were observed for both compounds. Although, 
small-molecule NAMs 21 and 40 might utilize the same binding site(s) as APLs, the possibility 
of difference in the binding site or in the binding manner could not be excluded.   
 
Overall, the study led to compound 40 which narrows the investigation window to a 
number of compounds that could guide us to a promising novel 7 nAChR small-molecule 
NAMs. Among the increasing reported evidence of the advantageous effect of 7 nACh receptor 
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inactivation on cognitive dysfunction, 7 nAChR-selective antagonists attenuated the undesired 
effects resulting from 7 nAChR–A1-42 interactions and tau protein hyperphosphorylation. So, 
if 7 nACh receptor antagonists are beneficial as symptomatic therapy for AD, small-molecule 
NAMs (guanidines) might represent a mechanistically unique approach.  
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VI. Experimental 
 
 
 
A. Synthesis 
 
Melting points were taken in a glass capillary on a Thomas Hoover melting point 
apparatus and are uncorrected. Proton nuclear magnetic resonance (1H NMR) spectra were 
obtained using a Bruker ARX 400MHz spectrometer at which peak positions are given in parts 
per million (δ) downfield from the internal standard tetramethylsilane (TMS). Infrared spectra 
were obtained on a Thermo Nicolet iS10 FT-IR. Purity of compounds was determined by 
elemental analysis performed by Atlantic Microlab (Norcross, GA) for the indicated elements, 
and the obtained values are within 0.4% of theoretical values. Reactions were monitored by thin-
layer chromatography (TLC) on silica gel GHLF plates (250 µm, 2.5 X 10 cm; Analtech Inc. 
Newark, DE), and Flash chromatography was performed on a CombiFlash Companion/TS 
(Teledyne Isco Inc. Lincoln, NE). 
 
N-(3-Chlorophenyl)-N-methylguanidine Hydrochloride (40). N-(3-Chlorophenyl)-N-
methylguanidine hydrochloride (40) was prepared according to a literature procedure.73 
Cyanamide (0.59 g, 14.03 mmol) was added to a solution of 3-chloro-N-methylaniline 
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hydrochloride (49) (1.70 g, 9.55 mmol) in absolute EtOH (15 mL). The reaction mixture was 
allowed to stir at reflux for 24 h, and then the reaction mixture was concentrated under reduced 
pressure. The residue was recrystallized from a mixture of absolute EtOH/Et2O to give 0.70 g 
(33%) of the desired product as white crystals: mp 259-261 °C (lit.73 mp 261-262°C); IR 
(diamond, cm-1): 3041, 3111 (NH), 3201 (NH2); 1H NMR (DMSO-d6) δ: 3.27 (s, 3H, CH3), 7.37 
(d, J = 7.24 Hz, 1H, ArH), 7.52 (m, 2H, ArH), 7.56 (m, 1H, ArH). 
 
3-Chloroformanilide (48). 3-Chloroformanilide (48) was prepared according to a literature 
procedure.91 A solution of 3-chloroaniline (47) (3.0 g, 23.5 mmol) in an aqueous solution of 
formic acid (95-97%, 10 mL) was heated at reflux for 30 min. The solution was then 
concentrated under reduced pressure and Et2O (20 mL) was added. The resulting solution was 
extracted by successive solvents: an aqueous solution of 5% citric acid (3×5 mL), H2O (3×5 
mL), and an aqueous solution of 5% NaHCO3 (3×5 mL).  The combined aqueous portion was 
extracted with Et2O (3×10 mL). The Et2O portion was then dried (MgSO4) and the solvent was 
removed under reduced pressure. The obtained solid was recrystallized from H2O to give 3.4 g 
(92%) of the desired product as tan-colored crystals: mp 45-47 °C (lit.91 mp 45-50 °C); IR 
(diamond, cm-1): 1595 (CO), 3073, 3194 (NH); 1H NMR (DMSO-d6) δ: 7.14 (td, J = 6.76, 1.10 
Hz,  1H, ArH), 7.35 (t, J = 8.02 Hz, 1H, ArH), 7.44 (dd, J = 8.24, 0.68 Hz, 1H, ArH), 7.79 (t, J = 
1.94 Hz, 1H, ArH), 8.29 (s, 1H, CH).  
 
3-Chloro-N-methylaniline Hydrochloride (49). 3-Chloro-N-methylaniline hydrochloride (49) 
was prepared using a literature procedure for a similar compound.92 A solution of 1 M BH3•THF 
(62.1 mL, 62.10 mmol) was added in a dropwise manner to a stirred solution of 3-
chloroformanilide (48) (3.00 g, 19.28 mmol) in anhydrous THF (10 mL). The solution was 
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heated at reflux under an N2 atmosphere for 3 h. The reaction mixture was allowed to cool to 
room temperature and a saturated solution of HCl in Et2O (30 mL) was added. The solution was 
then heated at reflux for 1 h. The THF was allowed to evaporate while stirring and heating and 
the reaction mixture was allowed to cool to room temperature. An aqueous solution of NaOH 
(15%, 30 mL) was added and the obtained mixture was extracted with Et2O (3×15 mL). The 
organic portion was concentrated under reduced pressure and a saturated solution of HCl in Et2O 
(50 mL) was added. The precipitate was collected by filtration and recrystallized from i-PrOH to 
yield 1.85 g (54%) of the product as yellow crystals: mp 160-162 °C (lit.93 mp 164 °C); IR 
(diamond, cm-1): 1597, 2634 (NH); 1H NMR (DMSO-d6) δ: 2.77 (s, 3H, CH3), 6.97 (m, 2H, 
ArH), 7.05 (s, 1H, ArH), 7.29 (t, J = 8.06 Hz, 1H, ArH). 
 
N-Methyl-N-phenylguanidine Hydrochloride (50). N-Methyl-N-phenylguanidine 
hydrochloride (50) was prepared according to a literature procedure.1 Cyanamide (1.23 g, 29.2 
mmol) was added to a solution of N-methylaniline hydrochloride (60) (2.00 g, 13.9 mmol) in 
absolute EtOH (14 mL). The stirred reaction mixture was heated at reflux for 58 h. Next, the 
solvent was removed under reduced pressure and the resultant solid was cooled to 0 °C. The 
solid was dissolved in absolute EtOH (14 mL), and the solution was heated at reflux, and was 
allowed to stir with charcoal for decolorization. After that, the mixture was filtered and the 
filtrate was evaporated under reduced pressure. The solid was dissolved in hot absolute EtOH 
(14 mL), the solution was cooled to room temperature, and Et2O was added until permanent 
turbidity was reached. The mixture was cooled to 0 °C to give a white precipitate that was 
collected by filtration and dried in an Abderhalden for 6 h to yield 0.87 g (34%) of the crude 
product. The solid was recrystallized from MeCN three times to give 0.53 g (21%) of the desired 
product as white crystals: mp (216.5-218 °C) (lit.85 mp 217-218°C); IR (diamond, cm-1): 1585, 
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1612, 3129 (NH), 3285 (NH2); 1H NMR (DMSO-d6): δ 3.26 (s, 3H, CH3), 7.35 (d, J = 7.32 Hz, 
2H, ArH), 7.43 (t, J = 7.38 Hz, 1H, ArH), 7.51 (t, J = 7.5 Hz, 2H, ArH). 
 
N-(3-Bromophenyl)-N-methylguanidine Hydrochloride (51). N-(3-Bromophenyl)-N-
methylguanidine hydrochloride (51) was prepared using a literature procedure for a similar 
compound.85 Cyanamide (154 mg, 3.66 mmol) was added to a solution of 3-bromo-N-
methylaniline (61) (407 mg, 1.83 mmol) in absolute EtOH (5 mL). The reaction mixture was 
allowed to stir at reflux for 24 h, and then the solvent was removed under reduced pressure. The 
resultant oily residue was crystallized from H2O to give 178 mg (37%) of the desired product as 
white crystals: mp 278-280 °C; IR (diamond, cm-1): 3118 (NH), 3276 (NH2); 1H NMR (DMSO-
d6) δ: 3.26 (s, 3H, CH3), 7.4 (qd, J = 8.06, 1.00 Hz, 1H, ArH), 7.47 (t, J = 7.96 Hz, 1H, ArH), 
7.64 (td, J = 7.92, 1.32 Hz, 1H, ArH), 7.68 (t, J = 1.86 Hz, 1H, ArH). Anal. Calcd 
(C8H10BrN3·HCl) C, 36.32; H, 4.19; N, 15.88.  Found: C, 36.23; H, 4.28; N, 15.77. 
 
N-(3-Flourophenyl)-N-methylguanidine Hydrochloride (52). N-(3-Flourophenyl)-N-
methylguanidine hydrochloride (52) was prepared using a literature procedure for a similar 
compound.85 Cyanamide (203 mg, 4.84 mmol) was added to a solution of 3-flouro-N-
methylaniline (62) (392 mg, 2.42 mmol) in absolute EtOH (10 mL). The reaction mixture was 
allowed to stir at reflux for 24 h, and then the reaction mixture was concentrated under reduced 
pressure. The residue was recrystallized from i-PrOH to give 112 mg (22%) of the desired 
product as white crystals: mp 197-199 °C; IR (diamond, cm-1): 3123 (NH), 3288 (NH2); 1H 
NMR (DMSO-d6) δ: 3.27 (s, 3H, CH3), 7.24 (dd, J = 7.36, 0.96 Hz, 1H, ArH), 7.29 (td, J = 8.60, 
2.40 Hz, 1H, ArH), 7.35 (d, J = 9.88 Hz, 1H, ArH), 7.56 (q, J = 8.06 Hz, 1H, ArH). Anal. Calcd 
(C8H10FN3·HCl) C, 47.18; H, 5.44; N, 20.63.  Found: C, 47.08; H, 5.57; N, 20.84. 
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N-(3-Iodophenyl)-N-methylguanidine Hydrochloride (53). N-(3-Iodophenyl)-N-
methylguanidine hydrochloride (53) was prepared using a literature procedure for a similar 
compound.85 Cyanamide (5.83 g, 13.88 mmol) was added to a solution of 3-iodo-N-
methylaniline (67) (1.87 g, 6.94 mmol) in absolute EtOH (18 mL). The stirred reaction mixture 
was heated at reflux for 24 h, and then the reaction mixture was concentrated under reduced 
pressure. The residue was recrystallized from absolute EtOH to give 0.55 g (25%) of the desired 
product as brown crystals: mp 285-287 °C; IR (diamond, cm-1): 3121 (NH), 3280 (NH2); 1H 
NMR (DMSO-d6) δ: 3.25 (s, 3H, CH3), 7.30 (t, J = 8.16 Hz, 1H, ArH), 7.41 (td, J = 8.00, 1.50 
Hz, 1H, ArH), 7.79 (m, 1H, ArH), 7.80 (m, 1H, ArH). Anal. Calcd (C8H10IN3·HCl) C, 30.84; H, 
3.56; N, 13.49.  Found: C, 31.07; H, 3.71; N, 13.28. 
 
N-(3-Methylphenyl)-N-methylguanidine Nitrate (54).  N-(3-Methylphenyl)-N-
methylguanidine nitrate (54) was prepared using a literature procedure for a similar compound.94 
An aqueous solution of cyanamide (50%; 1.5 mL) was added to a solution of 3-methyl-N-
methylaniline hydrochloride (63) (300 mg, 1.90 mmol) in absolute EtOH (25 mL). The stirred 
reaction mixture was heated at reflux for 25 h, and then cooled to 0 °C (freezer) for 24 h. The 
solution was concentrated under reduced pressure and was dissolved in H2O (3 mL). The 
solution was washed with Et2O (3 x 20 mL), followed by evaporation of H2O under reduced 
pressure. The resultant oily residue was dissolved in H2O (3 mL), followed by addition of 
NH4NO3 (380 mg, 4.74 mmol). The solvent was removed under reduced pressure and the 
resultant semisolid was recrystallized from H2O and, then, from a mixture of i-PrOH/Et2O to 
give 18 mg (6%) of the desired product as white crystals: mp 139-141 °C; IR (diamond, cm-1): 
3172 (NH), 3345 (NH2); 1H NMR (DMSO-d6) δ: 2.34 (s, 3H, CH3), 3.25 (s, 3H, CH3), 7.16 (d, J 
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= 7.88 Hz, 1H, ArH), 7.19 (s, 1H, ArH), 7.26 (d, J = 7.60 Hz, 1H, ArH), 7.40 (t, J = 7.72 Hz, 1H, 
ArH). Anal. Calcd (C9H13N3·HNO3) C, 47.78; H, 6.24; N, 24.77.  Found: C, 47.69; H, 6.29; N, 
24.86. 
 
N-(3-Methoxyphenyl)-N-methylguanidine Hydrochloride (55). N-(3-Methoxyphenyl)-N-
methylguanidine hydrochloride (55) was prepared using a literature procedure for a similar 
compound.85 Cyanamide (247 mg, 5.89 mmol) was added to a solution of 3-methoxy-N-
methylaniline (64) (512 mg, 2.94 mmol) in absolute EtOH (15 mL). The reaction was allowed to 
stir and heated at reflux for 24 h, and then the reaction mixture was concentrated under reduced 
pressure. The resulting residue was recrystallized from a mixture of absolute EtOH/Et2O to give 
310 mg (47%) of the desired product as off-white crystals: mp 219-221 °C; IR (diamond, cm-1): 
3122 (NH), 3292 (NH2); 1H NMR (DMSO-d6) δ: 3.27 (s, 3H, CH3), 3.79 (s, 3H, CH3), 6.93 (dq, 
J = 7.80, 0.72 Hz, 1H, ArH), 6.98 (t, J = 2.14 Hz, 1H, ArH), 7.01 (dt, J = 8.28, 1.84 Hz, 1H, 
ArH), 7.42 (t, J = 8.06 Hz, 1H, ArH). Anal. Calcd (C9H13N3O·HCl) C, 50.12; H, 6.54; N, 19.48.  
Found: C, 50.12; H, 6.60; N, 19.45. 
 
 3-Iodo-N-methylaniline Hydrochloride (67). 3-Iodo-N-methylaniline (67) was prepared 
according to a literature procedure.95 Two drops of H2SO4 was added to a mixture of 3-
iodoaniline (65) (2.00 g, 9.13 mmol) and trimethyl orthoformate (66) (1.49 mL, 13.69 mmol). 
The reaction mixture was heated at 120 °C in a distillation setup for 2 h and librated MeOH was 
collected. The solution was heated at 170 °C for 30 min and then was allowed to cool to room 
temperature. An aqueous solution of HCl (8 mL, 10%) was added and the mixture was heated at 
reflux for 3 h, then cooled to 0 °C (ice-bath) and neutralized with an aqueous solution of NaOH 
(20%, 15 mL). The reaction mixture was extracted with EtOAc (3×20 mL) and the organic 
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portion was concentrated under reduced pressure. The oily residue was purified by flash 
chromatography (silica gel; hexane/EtOAc; 9:1) and the resultant oil was dried under vacuum for 
6 h to yield 1.77 g (83%) of the free base of 67 as a yellow oil. The free base was dissolved in 
Et2O and a saturated solution of HCl in Et2O (70 mL) was added. The precipitate was collected 
by filtration and recrystallized from a mixture of absolute EtOH/Et2O to give 1.9 g (83%) of the 
product as brown crystals: mp 150-152 °C; IR (diamond, cm-1): 2897, 3194 (NH); 1H NMR 
(DMSO-d6) δ: 2.73 (s, 3H, CH3), 6.89 (d, J = 7.48 Hz, 1H, ArH), 7.02 (t, J = 7.92 Hz, 1H, ArH), 
7.18 (d, J = 7.52 Hz, 1H, ArH), 7.23 (s, 1H, ArH). 
 
B. Cell Transfection and Culture1a 
 
“Stably transfected HEK 293 cells expressing rat 34 or rat 7 and SH-EP1 cells 
expressing human 42 neuronal nAChRs, respectively, were prepared as described 
previously.96-99 All three cell lines were maintained at 37 C with 5% CO2 in the incubator. 
Growth medium for HEK 293 cells was minimum essential medium supplemented with 10% 
fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. The stably transfected cell 
line was raised in selective growth medium containing 0.7 mg/ml of geneticin (Invitrogen Corp, 
Carlsbad, CA). Growth medium for SH-EP1 cells was Dulbecco’s Modified Eagle’s medium 
with high glucose supplemented with 10% heat inactivated horse serum, 5% fetal bovine serum, 
100 U/ml penicillin, 100 mg/ml streptomycin, 8 mM L-glutamine, 1 mM sodium pyruvate, and 
0.25 mg/ml amphotericin (all from Invitrogen Corp, Carlsbad, CA). This stably transfected cell 
line was raised in selective medium containing 0.5 mg/ml zeocin (Invitrogen) and 0.4 mg/ml 
hygromycin B (Roche Diagnostics Corp, Indianapolis, IN).”66 
 
C. Whole-cell Current Recordings1a 
 
“Functional expression of nAChRs was evaluated in the whole-cell configuration of the 
patch-clamp technique using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, 
USA). The patch electrodes, pulled from borosilicate glass capillaries (Sutter Instrument 
Company, Novato, CA, USA), had a resistance of 2.5–3.5 MΩ when filled with an internal 
solution containing 110 mM Tris phosphate dibasic buffer, 28 mM Tris base, 11 mM EGTA, 2 
mM MgCl2, 0.1 mM CaCl2, and 4 mM Mg-ATP (pH adjusted to 7.3 with Tris base).99,100 In 
some cells, ~85% of electrode resistance was compensated electronically, so that the effective 
                                                             
a The studies were conducted in the laboratory of Dr. Abdrakhmanova. 
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series resistance in the whole-cell configuration was accepted when less than 20 MΩ. Stably 
transfected HEK cells were studied for 2–3 days after plating the cells on 15-mm round plastic 
cover slips (Thermanox, Nalge Nunc, Napierville, IL, USA). Generation of voltage-clamp 
protocols and acquisition of the data were carried out using pCLAMP 9.0 software (Molecular 
Devices). Sampling frequency was 5 kHz and current signals were filtered at 5 or 10 kHz before 
digitization and storage. All experiments were performed at room temperature (22–25 °C).  
 
Cells plated on cover slips were transferred to an experimental chamber mounted on the 
stage of an inverted microscope (Olympus IX50, Olympus Corporation, Tokyo, Japan) and were 
bathed in a solution containing 140 mM NaCl, 3 mM KCl, 2 mM MgCl2, 25 mM D-glucose, 10 
mM HEPES, and 2 mM CaCl2 (pH adjusted to 7.4 with Tris base). The experimental chamber 
was constantly perfused with control bathing solution (1–2 ml/min). The high-speed solution 
exchange system, HSSE-2 (ALA Scientific Instruments, Westbury, NY, USA), was used to 
deliver control and test solutions. Under optimal conditions, the delay in switching between 
solutions was ~10 ms. Data presented herein were obtained through subtraction from the leak 
current.”9 
 
D. Molecular Modeling 
 
The homology modeling studies were performed using SYBYL 8.1 (Tripos Inc. St. 
Louis, MO), Modeller (Version 9.7; University of California San Francisco, San Francisco, CA), 
GOLD (Version 5.0; Cambridge Crystallographic Data Centre, Cambridge, UK), and AutoDock 
(Version 4.1; Scripps Research Institute, La Jolla, CA). The sequence alignment of the three 
nAChRs was performed in Clustal X 2.0 using the following Protein Knowledgebase 
(UniProtKB) accession codes: P36544 (human 7 nAChR; Homo sapiens), Q05941 (rat 7 
nAChR; Rattus norvegicus), P04756 (mouse 1 nAChR; Mus musculus). The construction of the 
homology models was based on the crystal structure of the ECD of the mouse 1 nAChR 
subunit bound to -bungarotoxin at 1.94 Å resolution (PDB ID 2QC1). The initial models were 
energetically optimized using the Tripos Force Field (Gasteiger–Hückel charges, distance-
dependent dielectric constant = 4.0). Ligands were built in SYBYL and systematic search 
algorithm was applied (semi-empirical molecular orbital AM1 calculations) to prepare the four 
 
 
89 
 
low-energy rotamers. PROCHECK program was used for geometry quality assessment of the 
models.  
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Appendix A 
 
Primary binding assay for the N-methyl series compounds 40 and 50-55 at 10 µM concentration 
 
 
 
 
 
 
 
a  N = 4 determinations; radioligand for 5-HT3=[3H] LY278584; and for all nAChRs = 
[3H]epibatidine. 
b ND not determined. 
** = all are cloned except where marked, (endogenous rat forebrain). 
Compound R 
 Ki (nM)a 
5-HT3 22 24 32 34 42 42** 44 
40 Cl > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 
50 H > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 
51 Br > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 
52 F > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 
53 I > 10,000 > 10,000 > 10,000 NDb > 10,000 > 10,000 > 10,000 > 10,000 
54 CH3 NDb > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 
55 OCH3 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 > 10,000 
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